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ABSTRACT 
The predominance of left-handedness in amino acids and proteins in living organisms is 
well established. The presence of D-amino acids in the prokaryotes (e.g., bacterial cell wall and 
lantibiotics) has been considered exceptions to this rule. In the animal kingdom, proteins are 
thought to be more strictly built in the L-form due to the chiral selectivity of ribosome-based 
protein synthesis mechanism. However, in recent years it has become evident that certain residues 
within a peptide can be inverted to the D-form in an enzyme-mediated post-translational process, 
forming D-amino acid-containing peptides (DAACPs). 
 DAACPs adopt different three-dimensional structures due to epimerization, and hence, 
different physicochemical properties and binding affinities to their cognate receptors. These 
changes have profound consequences on physiological effects. Most of the known DAACPs were 
found to have greater physiological activities compared to their L-form precursors; and 
configurational changes also result in resistance to enzymatic digestion, which affects their life 
cycle and metabolization at the site of action. 
DAACP Identification is a necessary step toward better understanding of the 
physiological significance of this modification. More than 30 D-amino acid-containing peptides 
(DAACPs) have been discovered in metazoan species since the early 1980s. Hormones, 
antimicrobial peptides and toxins have been found in this list; and in several cases, neuropeptides, 
a group of cell-to-cell signaling molecules found in the neural tissues, were also shown to 
undergo such modifications. DAACPs are distributed across different species in several animal 
phyla, Arthropoda, Mollusca, and Chordata, indicating a wide presence and conservation through 
evolution. Unfortunately, discoveries of these unusual peptides were oftentimes serendipitous 
findings that originated from unexpected results from bioassays using the synthetic all-L peptides, 
and currently there’s no systematic approach to study the presence of these molecules. 
Conventional peptide sequencing and mass spectrometry-based proteomics approaches do not 
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distinguish L- from D-form residues, either. Therefore, we ask the question: how many more 
DAACPs have been neglected because of a lack of appropriate analytical methods?  
How does one differentiate an endogenous neuropeptide—one that contains an amino 
acid in the D-form—from a complex mixture containing partially characterized brain peptides 
with concentrations spanning many orders of magnitude? Even without analyzing for DAACPs, 
this is already a complex measurement challenge. A peptidomics experiment that also seeks to 
determine D-amino acids present in such samples represents a much more difficult task than 
quantifying the amino acid configurations of several synthetic peptides, which is the sample type 
often used when developing characterization approaches. Therefore, methods need to be carefully 
selected. 
The development and application of a systematic approach to identify DAACPs from the 
central nervous systems is presented. Using the classic neurophysiological model organism the 
sea hare Aplysia californica, a suite of analytical methodologies have been integrated into a 
discovery funnel that allows identification of DAACPs from complex biological samples. With 
some modifications, these methods can be applied to a wide range of animal systems including 
mammals, to test the hypothesis that DAACPs are more common than we currently know.  
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CHAPTER 1  
 
INTRODUCTION AND DISSERTATION 
OVERVIEW 
1.1 INTRODUCTION 
 
Neuropeptides are neuroactive peptides produced in the brain and gut, and exert direct effects on 
central as well as peripheral nervous systems through specific neuropeptide receptors.1 They act 
as neurotransmitters, neuromodulators and neurohormones, and regulate a variety of different 
physiological processes such as food intake, reproduction, sleep, pain, mood regulation, and 
learning and memory.  
Precursor proteins called pre-prohormones are first synthesized by the ribosomes, and 
their signal peptides are cleaved in the synthesis process to form the prohormones. The large and 
inert prohormones are transported to the Golgi network where they are packaged with processing 
enzymes and bud off to form large dense-core vesicles. In the transit through trans-Golgi network 
and to the nerve terminals where they are released, proteolysis and post-translational 
modifications (PTMs) take place. Prohormones are excised into shorter peptides which can have 
quite different functions depending on their sequences, modifications, and targeted locations.2  
Pre-mature peptides undergo a range of PTMs. Except for N-glycosylation and disulfide 
bond formation which happen in the Endoplasmic Reticulum, most PTMs take place in the trans-
Golgi network and later in the secretory granules. These modifications involve chemical changes 
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to the peptide backbone that introduce changes to physicochemical properties of the 
neuropeptides. These changes can modify many aspects of the function of the molecule, but 
oftentimes are ascribed as having a major function.  Some may confer more stability (such as 
amidation, acetylation, pyroglutymylation, and disulfide bond formation), solubility (sulfation), 
binding affinities (acetylation and amidation), and longer lifetime after release (L- to D-
isomerization).3-4 Structural changes can happen as well, for example, disulfide bond formation 
that modifies all aspects of the peptide. By post-translational modification, a diverse range of 
molecules can be produced from a limited number of genes; and these modifications are usually 
required for proper physiological function. 
The unusual PTM, L-to-D epimerization in peptides, remains a rare phenomenon,5-6 due 
to lack of analytical methodology to identify this isobaric modification; however, the profound 
impact it has on the neuropeptides in both receptor-binding properties and metabolization as a 
signaling molecule makes it an important PTM to study. More background information about 
DAACPs will be introduced in Chapter 2. 
The Sweedler group has extensive experience studying neuropeptide synthesis, 
processing, and release, and in developing analytical tools for high-throughput and trace-level 
analysis of neuronal signaling molecules. Our group has successfully conducted 
neuropeptidomics studies in a range of important model organisms, including molluscan species, 
planarian, honey bee, rat and mouse.7-11 The existing sequence and distribution information of a 
large number of neuropeptides in these organisms can be leveraged to facilitate the identification 
of isomerized residues.  
We will use Aplysia as a model organism for initial method development. Aplysia has a 
similar sized genome and is chemically as complex as mammals, but its brain is much simpler. As 
is found throughout Metazoa, it has well conserved neurochemistry. After all, in every animal 
nervous system studied to date, the neurons use glutamate, aspartate, serotonin, dopamine, 
GABA, nitric oxide, and other molecules as neurotransmitters.  In addition, many neuropeptide 
families are ancient and well conserved across multiple phyla. Therefore, it is not surprising that 
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neuropeptides from mammalian system have counterparts in Aplysia, for example insulin12.  
Aplysia has been established to be a successful neurobiology model because its behaviors 
and neuronal networks underlying these behaviors have been well characterized. Some behaviors 
have been mapped to activities in specific neurons in defined neural networks and the 
neurotransmitters involved in the dynamics of the networks have been identified and studied. By 
using this model, the exploration of DAACPs’ physiological significance is facilitated, and this 
knowledge proves useful for investigations of higher organisms. Newly discovered DAACPs can 
be related to existing knowledge about the corresponding prohormones, which can then be 
mapped to specific anatomical structures and very well-understood neuronal networks. The 
relatively easy access to the CNS of Aplysia gives us the opportunity to look at the distribution of 
these DAACPs in the future using MS imaging techniques. The identifiable neurons will make it 
possible to study the release of these peptides from specific cells as well.  
Aiding these studies there is one known DAACP in Aplysia, a cardioexcitatory peptide 
NdWFa,13 as well as genes found that are homologs to other DAACPs. This indicates there’s an 
isomerization mechanism in this organism, and thus it is more likely this mechanism also works 
on other peptides as well. 
 
1.2 DISSERTATION OVERVIEW 
 
Chapter 2 will give an overview of existing knowledge and analytical tools available for DAACP 
analysis. This chapter opens with reviewing discoveries of ~30 currently known DAACPs, and 
continues on to introduce non-chiral methods to directly separate diastereomers, followed by 
cases where chiral selectors are employed either in the stationary or the mobile phase. Other 
methods such as nuclear magnetic resonance (NMR), mass spectrometry (MS), and those that 
involve breaking peptides down to analyze are also introduced.  
The approaches we have developed and applied fall into two categories: targeted and 
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non-targeted. The targeted approach is a focused analysis of certain candidates that are potential 
DAACPs, including the peptides that are homologous to known DAACPs in related species. One 
approach, among several others, is to use tandem MS and analyze the unimolecular fragmentation 
patterns of diastereomeric peptides. A rapid and sensitive method for the fragmentation pattern 
analysis with MALDI-TOF/TOF for synthetic peptide pairs and small biological samples such as 
single cells will be detailed in Chapter 3. Using this method, we successfully identified the 
DAACP, NdWFa, as in the D-form, and measured the isomeric content of the D-form.  
This method, applied to a peptide of interest, GFFD (or GdFFD), returned promising 
results showing that the endogenous form has similar fragmentation pattern with the D-form, or 
between L- and D-form. LC-MS was used to verify this result, and both retention time and 
fragmentation pattern compared with synthetic standards supported the discovery of GdFFD in 
Aplysia. This result will be described in detail in Chapter 4. In this chapter, another peptide 
YAEFLa (or YdAEFLa), homologous to the Achatina YdAEFLa, was tested for the presence of 
the D-Ala as well. However, only L-form was observed in the tissues that were scanned. This 
peptide, unlike GdFFD, is not modified the same way as in Achatina. 
Assuming little prior knowledge, it is challenging to identify DAACPs in a blind 
screening with a complex biological sample. We have established a multi-stage discovery 
platform integrating several interconnected approaches. The first step, introduced in Chapter 5, 
comprises of screening approaches which discriminate between all-L peptides and DAACPs. This 
step can take a sample containing many peptides spanning several orders or magnitude in 
concentration, and identify a subset of them for further tests. One of these methods exploits the 
resistance of DAACPs to enzymatic digestion by using an aminopeptidase to digest a complex 
mixture of peptides. This can also serve as an enrichment step for low-abundant DAACPs 
because the all-L peptides are digested by the peptidase. The other method is aimed toward 
identifying structural heterogeneity of one m/z if it corresponds to two diastereomers coexisting 
in one sample.  
This subset of potential DAACPs are then investigated with a more rigorous chiral amino 
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acid analysis step. Due to the unpredictable nature of possible analytes generated from biological 
samples, Chapter 6 illustrate three methods for chiral amino acid analysis which complement 
each other and can provide thorough analysis for all peptide candidates generated from the first 
step. Chiral Edman degradation is suitable for a big sample containing a relatively pure peptide 
with unknown sequence because it allows simultaneous sequencing and chirality analysis; it can 
also be automated for high-throughput analysis. Capillary electrophoresis analysis of peptide 
hydrolysates is a very sensitive and quantitative approach, which can be applied to a low-
abundant peptide of interest; the quantitative capability will allow the isomeric content of the 
DAACP to be measured at the same time. LC-MS/MS-multiple reaction monitoring (MRM) 
analysis of peptide hydrolysates is a high-throughput and fairly sensitive technique, and the triple 
quadrupole mass spectrometer used to perform such analysis is also suitable for quantitative 
analysis. The last method will be the major focus although some data obtained from synthetic 
peptides will be presented for the first two methods as well. Biological samples containing 
GdFFD was analyzed with the MRM method and the dF residue was identified in a un-biased 
fashion, showing this workflow is suitable for identifying DAACPs from biological samples in 
spite of the possible racemization of L- to D-amino acid in the hydrolysis process.    
Research described in this volume represents an attempt to probe the presence of peptides 
that adopt an unusual chiral form in the metazoan species. These probably overlooked 
neuropeptides may constitute an important category of signaling molecules. This research builds 
upon extensive knowledge and expertise in the group and in the Biotechnology Center in the 
University of Illinois, in neuropeptidomics, small-volume analysis, analytical method 
development, biochemistry, and understanding of molluscan model organisms.  Collaboration 
with industrial research lab and research groups in other universities provided unique 
opportunities to explore the use of other instruments and methods to characterize DAACPs. 
Complementing analytical measurements of the component of the central nervous system (CNS), 
expertise of our collaborators in neurophysiology, molecular genetics and immunochemistry 
provided insights from biological perspectives and are pivotal for a more complete understanding 
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of the roles DAACPs play in the CNS. 
This research will fit into our long-time interests in understanding neuropeptides as a 
class of dynamic and robust neuronal messengers, and chirality in the CNS. With this toolbox for 
DAACP characterization, we will be able to test the hypothesis whether DAACPs are more 
common than we thought. Immediate applications to the well-define Aplysia system and with 
minor modifications, to a wider range of species will generate a better understanding of this PTM 
and the basic mechanisms of receptor recognition and intercellular signaling.  
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CHAPTER 2  
 
ANALYTICAL TOOLS TO CHARACTERIZE D-
AMINO ACID-CONTAINING PEPTIDES 
Notes and Acknowledgements  
 This chapter is adapted from a review article reused with kind permission from Springer 
Science+Business Media: Analysis of endogenous d-amino acid-containing peptides in Metazoa, 
Volume 1, Number 1, 2009, 7-24, Lu Bai, Sarah Sheeley and Jonathan V. Sweedler.1 This 
material is based upon work supported by the National Science Foundation under Award No. 
CHE-04-00768, the National Institutes of Health under Award No. NS031069 and the National 
Institute of Drug Abuse under Award No. DA018310 to the UIUC Neuroproteomics Center on 
Cell-Cell Signaling. 
 
2.1 ABSTRACT 
 
Peptides are chiral molecules with their structure determined by the composition and 
configuration of their amino acid building blocks. The naturally occurring amino acids, except 
glycine, possess two chiral forms. This allows the formation of multiple peptide diastereomers 
that have the same sequence. Although living organisms use L-amino acids to make proteins, a 
group of D-amino acid-containing peptides (DAACPs) has been discovered in animals that have 
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at least one of their residues isomerized to the D-form via an enzyme-catalyzed process. In many 
cases, the biological functions of these peptides are enhanced due to this structural conversion. 
These DAACPs are different from those known to occur in bacterial cell wall and antibiotic 
peptides, the latter of which are synthesized in a ribosome-independent manner. DAACPs have 
now also been identified in a number of distinct groups throughout the Metazoa. Their 
serendipitous discovery has often resulted from discrepancies observed in bioassays or in 
chromatographic behavior between natural peptide fractions and peptides synthesized according 
to a presumed all-L sequence. Because this L-to-D post-translational modification is subtle and 
not detectable by most sequence determination approaches, it is reasonable to suspect that many 
studies have overlooked this change; accordingly, DAACPs may be more prevalent than currently 
thought. Although diastereomer separation techniques developed with synthetic peptides in recent 
years have greatly aided in the discovery of natural DAACPs, there is a need for new, more 
robust methods for naturally complex samples. In this review, a brief history of DAACPs in 
animals is presented, followed by discussion of a variety of analytical methods that have been 
used for diastereomeric separation and detection of peptides. 
 
2.2 INTRODUCTION 
 
It has long been assumed that in higher animals, natural amino acids exist exclusively in the L-
form. In the L-form, the -COOH, -NH2 and -R groups are arranged clockwise around the chiral 
carbon atom, as shown in Figure 2.1, with the hydrogen atom located away from the center; for 
the D-form, these groups are  arranged counterclockwise around the chiral carbon atom. In recent 
years several D-amino acids have been found in the nervous system. These D-amino acids have 
been correlated with a number of diseases 2-4 and may be novel players in neurotransmission and 
development. Peptides that contain D-amino acids are even less understood than free D-amino 
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acids in higher animals and such peptides have now been found in a surprising range of animals 
(Figure 2.2). While antibiotic peptides in bacteria and the peptidyl glycan in their cell walls 5 
indicated their existence in prokaryotes, the presence of only L-amino acids in peptides in higher 
organisms was accepted as an “unbreakable” norm, with the exception that a small fraction of the 
amino acids perhaps have racimized during aging. Naturally existing D-amino acid-containing 
peptides (DAACPs) did not receive the awareness and attention they enjoy today until 1981, 
when the D-alanine-containing peptide, dermorphin, was isolated.6 Over the last three decades, 
more than 30 examples of DAACPs in animals have been reported.  Interestingly, they distribute 
in a number of different species, ranging from frogs 6-11 to snails,12-26 crustaceans 27-28 spiders,29 
and even mammals,30-31 spanning five phyla (Table 2.1). Importantly, isomerization of the residue 
has been found to be crucial for proper biological function. As one example, the cardioactive 
peptide NdWFa (named after its sequence; each amino acid is represented by its one letter 
abbreviation, the letter following a “d” indicates that amino acid is in D-form, and “a” means 
amidation of the C-terminal residue.), isolated from two subspecies of Aplysia, has been found to 
be significantly more effective in enhancing the beating amplitude of an Aplysia heart at 10-10 M. 
However, the synthetic peptide NWFa has little effect, even at 10-6 M, indicating that the 
modification is essential for proper physiological function.14 Why is this the case? It may be 
because naturally existing DAACPs, rather than their synthetic all-L-form counterparts, interact 
with the endogenous receptors to cause the required physiological responses.32 It is also thought 
that the modified structure of DAACPs makes it more difficult for the peptides to be digested by 
endogenous peptidases, thus increasing the time DAACPs remain active.27 DAACPs have been 
the subject of several reviews, with an excellent review emphasizing the biology of DAACPs by 
Kreil G. et al.33 and another describing analytical approaches used to characterize natural 
DAACPs and other mammalian chiral peptides by Iida et al. 34  
Because DAACPs are naturally occurring peptides, a study to determine unknown 
peptides in a sample may now require a stereoselective analysis to characterize the peptide 
complement, for example, from a brain or toxic secretion. Of course, stereoselective 
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measurements can be important for drug development and manufacture. For many pharmaceutical 
companies, stereospecific analyses are important for ensuring quality control, and are required by 
regulatory authorities such as the U.S. Food and Drug Administration, and the European 
Medicines Agency (EMEA) because isomers usually possess different, and sometimes undesirable 
pharmacokinetic and toxicological profiles. On the other hand, just as endogenous DAACPs are 
recognized stereoselectively by receptors, the chirality of peptide-based drugs can affect their 
efficacy and metabolism in many ways, so that specific stereoisomers can be more efficacious 
drugs than their isomers.  
 Although several methods are amenable to peptide analyses, due to the ever improving 
performance capabilities of modern mass spectrometry (MS), most peptide measurement efforts 
use this approach extensively.35-38 However, one of the challenges of detecting DAACPs lies in 
the zero mass shift of this modification, making them difficult to characterize using MS alone. 
Various analytical techniques are available that allow the physicochemical changes effected by 
conformational alteration to be measured, and a number are separation-based. The separation of 
peptide diastereomers depends on differences in the physicochemical properties of the all L-
amino acid-containing peptides (LAACPs) and the DAACPs, and these changes are usually 
magnified with the use of chiral selectors embedded in stationary phases or added into mobile 
phases. The use of separations using chiral stationary phases (CSPs) and chiral mobile phase 
additives (CMPAs) in high performance liquid chromatography (HPLC) and capillary 
electrophoresis (CE) are highlighted below. Also discussed are MS and nuclear magnetic 
resonance (NMR) spectroscopy, as are hybrid approaches such as selective enzymatic digestion 
followed by MS characterization.  
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2.3 DAACP DISCOVERY: HISTORY AND BIOLOGICAL 
PERSPECTIVES  
 
While L-amino acids are utilized exclusively by ribosomes in translation, amino acids in the D-
form have been found to exist in several antibiotic peptides such as gramicidin and tyrocidin.5 It 
was later demonstrated that these peptides are assembled via thioester intermediates 39 through 
non-ribosomal pathways on multi-enzyme complexes in a stepwise fashion. Lantibiotics, a 
different class of peptide antibiotics derived from larger precursors produced by bacteria, also 
contain D-amino acids. These peptides, including nisin, subtilin, epidermin and cinnamycin, 
achieve their final forms via post-translational processing of the pre-peptides.40-41  
 Despite this knowledge, production of DAACPs has been considered primarily a 
prokaryotic function because eukaryotic cells use only L-amino acids in ribosome-mediated 
protein synthesis. However, since the discovery in 1981 of dermorphin, a bioactive DAACP 
isolated from skin secretions of the South American tree frog Phyllomedusa sauvagei,6 the notion 
that DAACPs are present in higher organisms began receiving greater attention. With D-alanine 
in the second position, dermorphin demonstrated high affinity and selectivity for μ-type opiate 
receptors—on a molar basis, 1000 times more analgesic potency than morphine—however, the 
all-L-form counterpart was devoid of bioactivity.7, 9, 32 It was later shown that the D-alanine 
residue was encoded by the normal alanine codon GCG, suggesting that occurrence of the D-
amino acid was via a post-translational modification (PTM).42 In the skin of the same frog 
species, as well as the sub-family Phyllomedusinae, researchers identified additional opiate 
peptides that contained D-amino acid residues. The deltorphins for example, are a class of 
DAACPs found to exhibit high selectivity and affinity for the δ-type opiate receptor.7-10, 32 
Interestingly, the amino terminal of the opioid peptides described above share the same sequence, 
Tyr-Xaa-Phe, where Xaa represents D-Ala, D-Met or D-Leu.33 Other DAACPs discovered in frog 
skin secretions are the Bombinins, a peptide family isolated from Bombina variegata that exhibit 
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antimicrobial activity, containing D-alloisoleucine instead of isoleucine.11, 43  
 DAACPs have also been identified in mollusks. Conotoxins in Conus venom represent a 
class of peptides that are heavily post-translationally modified, and more than 12 members 
belonging to the I- and M-superfamilies of conotoxin were found to contain a D-amino acid. 
Some of these DAACPs have L-to-D isomerization at the third or fourth residue from the amino 
end, and several such as conophan, conomarphin, r11a, r11b, and r11c have the D-residue at the 
third position from the C-terminus. Other molluscan neuropeptides were also found to be 
DAACPs. Achatin I (GdFAD) from the African giant land snail Achatina fulica was the first 
discovered peptide in this category.12 While the D-amino acid-containing native peptide has 
potent neuroexcitatory effects, the all-L-form isomer achatin II (GFAD) lacks activity altogether. 
Fulicin (FdNEFVa) 44 and fulyal (YdAEFLa),13 two peptides from the same species, were shown 
to be produced from the same prohormone precursor. As mentioned earlier, NdWFa from Aplysia 
has a more potent effect on heart rate than the all-L-form isomer, found in two sub-families.14, 45  
 Among the diverse species in which DAACPs have also been discovered are crustacea 
(cHHA, cHHB, Prc CHH-II),27-28 octopus (ocp-1/4) 25 and spiders (in venom) (IVB).29 The 
presence of DAACPs in platypus venom 30-31 demonstrated that these peptides can be found in 
mammals, and certainly raised questions about how prevalent DAACPs actually are and if many 
have been overlooked in peptide characterization studies.  
 Before describing methods to characterize them, it is worth briefly discussing the 
function of this unusual modification. The incorporation of a D-amino acid into a peptide 
sequence appears to serve several functions: first, this modification allows more products from a 
single gene; second, a variety of physiological functions can be achieved through different 
binding to the peptide’s cognate receptor; and third, the altered structure can result in a distinct 
(usually greater) resistance to protease degradation and thus confers a different effective time 
frame.  
 Increasing evidence suggests that the L-to-D conversion is a PTM, not only because a 
normal codon has been found at the D-residue position 42 but more importantly, peptide 
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isomerases from spider, frog and platypus have been isolated.46-48 The spider isomerase is a 
cofactor-independent enzyme that has sequence similarities with serine protease. In spider 
venom, it selectively catalyzes the conversion of a serine residue at the third position from the C-
terminus, instead of the one in the middle region, indicating the specificity of this enzyme partly 
depends on steric factors.33, 49 Frog isomerase is thought to be a different type of enzyme, at least 
according to its sensitivity to chelators and inhibitors. These two enzymes seem to have differing 
preferences on the location of catalysis as D-amino acids have been found at different termini 
between frog and spider. Although the snail isomerase is not known, the relative location of D-
amino acids in a peptide sequence is at the second position from the N-terminus, resembling most 
DAACPs from frog sources. Platypus isomerase is stable at temperatures as high as 55 oC, 
indicating a robust structure,48 but unfortunately, sequence information has yet to be determined 
due to difficulties in purification. Additionally, using ultrastructural immunohistochemistry, 
Gallois et al.50 demonstrated that isomerization of the D-Phe residue in CHH occurs within the 
secretory granules. The fact that only a fraction of the CHH was in an isomerized form may 
indicate equilibrium between precursor and processed peptides.  
 
2.4 ANALYTICAL TECHNIQUES USED TO CHARACTERIZE 
DAACPS  
 
How does one differentiate an endogenous brain peptide—one that contains an amino acid in the 
D-form—from a complex mixture of partially characterized brain peptides present within an even 
more complex peptide mixture spanning many orders of magnitude in concentration?  Even 
without analyzing for DAACPs, this is a complex measurement challenge. A new direction in 
peptide research has emerged in response to such analytical challenges, the field of 
peptidomics.35-36, 51-52 A peptidomics experiment that also seeks to determine DAACPs present in 
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such samples represents a much more difficult task than quantifying the amino acid 
configurations of several synthetic peptides, which is the sample type often used when developing 
characterization approaches. We begin our discussion with a series of common separation-based 
methods for characterizing endogenous DAACPs within the framework of chiral selection. So as 
to highlight certain aspects of these measurement approaches, a number of examples of standard 
peptide separations are included. Following separations, we examine several non-separation 
measurement techniques: mass spectrometry (MS), nuclear magnetic resonance (NMR) and 
peptide digestion.  
 
2.4.1 Non-Chiral Separations 
Many DAACPs were discovered because they possess different properties from the all-L isomers. 
Intrinsic differences in these peptide diastereomers-pKa values, polarities, hydrodynamic radii—
have been exploited in many DAACP separations using high performance liquid chromatography 
(HPLC), with several widely adopted for capillary electrophoresis (CE).   
 
High Performance Liquid Chromatography. HPLC is the most commonly used separation 
technique for peptides. Therefore, it should not be surprising that it is the most prevalent method 
in DAACP investigations, partly owing to its ability to discriminate between diastereomers using 
non-chiral (such as C18) columns and chiral stationary phase-based columns, its relative low cost, 
and high throughput. Except for rare cases where diastereomers exhibit similar retention behavior 
using reversed-phase (RP) HPLC,13 most known DAACPs have been separated using achiral 
columns in RP HPLC. Ion-exchange chromatography has also been successful in this application 
but is not as often used.  
 A number of research groups have used LC to successfully investigate DAACPs.  Kreil et 
al. 7 showed that deltorphin (YdMFHLMDa), which was produced from the same cDNA of the 
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dermorphin precursor, could be baseline-separated from the L-Met2 diastereomer using an RP-
HPLC column (Figure 2.3). Also using this approach, Fujisawa and colleagues 26 separated the 
molluscan peptide mytilus-FFRFamide (AdLAGDHFFRFa) from seven isomers with a D-amino 
acid at other positions in the peptide. They further confirmed the existence of D-Leu in the native 
peptide by amino acid analysis; they derivatized the acid hydrolysates and separated the resulting 
amino acid products using HPLC. The retention of another D-amino acid-containing neuropeptide 
isolated from A. fulica, fulicin (FdENFVa), was compared with its all-L isomer and other 
diastereomers, each with one of the five amino acids substituted with an amino acid in the D-
form.44  Each diastereomer was eluted at different times using an anion-exchange column. Co-
elution of native fulicin with synthetic FdENFVa helped to confirm the identity of the peptide. 
From the same precursor, a fulicin-related peptide, fulyal, was discovered.13 This study 
investigated the chromatographic behaviors of fulicin and nine fulicin gene-related peptides 
(FGRP 1-9) with the all-L-amino acid form and a D-residue in the second position using RP 
HPLC. Except for fulicin, which has a similar retention time as its L-isomer, the other FGRP 
peptide diastereomers were all separated. Additional examples of DAACPs discovered using 
similar approaches can be found in Table 2.1. Note that synthetic peptide standards have been 
used to confirm the identifications. 
 Also of interest are the experimental parameters that influence separation. Chen et al 53 
examined the effects of mobile phase conditions, temperature, and column packing on the RP-
HPLC retention behavior of seven peptides derived from the amphipathic peptide Ac–
EAEKAAKEXEKAAKEAEKa, with a position in the middle of the hydrophobic face of the α-
helix (the ninth residue) representing an L- or a D-amino acid. Proper stationary phase selection is 
important; for example, when using a Zorbax Eclipse XDB-C8 column, seven model peptides, 
including three diastereomeric pairs, were baseline separated. At pH 2.0, increasing 
trifluoroacetic acid or adding sodium perchlorate (NaClO4) into the mobile phase improved the 
peak shape because these compounds acted as hydrophilic anionic ion-pairing reagents; the 
retention time increased through ion-pairing effects with the positively-charged peptides. 
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Alternatively, using a Zorbax 300 SB-C8 column and increasing temperature from 20°C to 65°C 
and/or 80°C served to decrease retention time while improving peak shape. This was due to the 
increased mass-transfer rate of peptides between mobile and stationary phases. Because not all 
decreases in retention time were proportional, QD (with the X residue replaced with D-glutamine) 
and PL co-eluted at 80°C. The two columns showed different selectivity for the following peptide 
pairs: D,L-Pro, D,L-Ser, and D,L-Gln (at pH 2.0); six peptides were separated at pH 7.0 on both 
columns. 
 
Capillary Electrophoresis. CE separations are based on charge and molecular shape, and are 
categorized into several modes.54-56 Many peptide diastereomers, especially small ones, can be 
resolved in CE using simple phosphate buffer systems without adding chiral selectors. 
Enkephalin-related peptides, including two pairs of diastereomers, have been separated using 
CE,57 with sodium dihydrogen phosphate as the buffer system. A decrease in pH shortens 
separation time and improves separation efficiency, and in this case, a pH slightly higher than 3 
was found to be optimal.  
 A variant of CE is capillary electrochromatography (CEC). Open-tubular CEC, using a 
C8-coated capillary with an aqueous solution of a perfluorinated acid ion-pairing reagent at high 
concentrations (up to 400 mM) as background electrolyte, was employed for a novel ion-
interaction CE system.58 A series of synthetic 18-residue, amphipathic alpha-helical peptide 
diastereomers related to Ac–EAEKAAKEAEKAAKEAEKa, with X substituted by 19 L- or D-
amino acids, were used as model peptides. The perfluorinated acid ion-pairing reagent is 
important for this separation. The same set of model peptides was used to investigate the 
separation capacities of various CE methods, including capillary zone electrophoresis (CZE), 
micellar electrokinetic chromatography (MEKC) (with uncoated capillary in the presence of 3-
[(3-cholamido-propyl)dimethylammonio]-1-propanesulfonate), and open-tubular CEC (with C8-
coated capillary in the presence of 25% 2,2,2-trifluoroethanol or 25% ethanol).59 The open 
tubular-CEC methods performed better with peptides containing hydrophilic side chains, and 
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MEKC better separated those containing hydrophobic or aromatic side chains. 
 
2.4.2 Chiral Separations 
Although peptide diastereomers can be discriminated from each other based on differences in a 
variety of physicochemical properties such as pKa, shape, and hydrophobocity, the use of chiral 
selectors often makes separations easier. Diastereomeric analytes form transient complexes based 
on the affinity of the analyte to the chiral selector, and thus result in different retention behaviors 
or electrophoretic mobilities. The following section focuses on the methods used to separate 
DAACPs from LAACPs when chiral selectors are employed, highlighting work with both 
synthetic and natural peptides, and the discussion organized according to separation mode. Chiral 
selectors are categorized as chiral stationary phases (CSPs) or chiral mobile phase additives 
(CMPAs), with both used in partition chromatography and CMPAs used in CE. A surprising range 
of CSPs have been developed, with a large fraction now commercially available. Categories of 
CSPs include Pirkle-type, cellulose, cyclodextrin, ligand-exchange, crown ethers, glycopeptides, 
macrocyclic antibiotics, and proteins.60 As it is impossible to include all the diastereomer peptide 
separations using CSPs and CMPAs from previously published papers, several examples are 
presented here, first grouped by separation mode and then by type of selector(s) used. 
 
High Performance Liquid Chromatography. While enantiomeric separations require a chiral 
selector, as described above, diastereomers can be resolved using RP or ion-exchange columns 
without a chiral additive or stationary phase. The addition of a chiral selector such as a CSP often 
improves the resolution between peptides and usually does not require peptide derivatization, and 
therefore has become an effective means of DAACP/LAACP separation. Because the goals of 
characterizing endogenous DAACPs are often to understand peptide function, and the goals of 
synthetic DAACP/LAACP separations are to understand and optimize the separation approaches, 
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most comparisons have involved synthetic peptide mixtures. In what follows, several of the more 
common CSP categories are briefly described in relation to DAACP separations. 
 Crown ethers, later shown to have significant chiral selectivity, were first introduced by 
Pederson in 1967,61 earning him the Nobel Prize in Chemistry in 1987. Crown ethers have 
become one of the most significant categories of CSPs. While there are a variety of crown ether 
CSPs, these macrocyclic polyethers all have cavities with chiral selectivity, the inner side of 
which is lined with oxygen atoms. One of the most widely used, commercially available CSPs, 
Crownpak CR, was developed by immobilizing (3,3’-diphenyl-1,1’-binaphthyl)-20-crown-6 onto 
C18 silica gel. Stereoisomers of tripeptide Ala-Ala-Ala have been successfully separated using 
this column.62 Another example of a crown ether-based CSP has a tartaric acid unit, for example, 
(-)-(18-crown-6)-2,3,11,12-tetracarboxylic acid (Figure 2.4A) used by Conrad et al.63 to resolve 
enantiomers of dipeptides and tripeptides (Figure 2.4B). Crown ethers have also been used as the 
chiral selector added to background electrolyte in CE,64-66 covered later in this review. 
 Another common category of CSP includes macrocyclic glycopeptide antibiotics, which 
were introduced as chiral selectors by Armstrong and co-workers in 1994,67-68 and first used in 
thin layer chromatography and CE separations of racemic drugs and amino alcohols. This class of 
chiral selectors predominantly includes many natural products: vancomycin, teicoplanin and 
ristocetin A. The anchoring sites on macrocyclic glycopeptides such as amine groups and/or 
carboxyl groups interact with ionizable groups on analytes and provide the basis for chiral 
recognition. Interacting forces between the CSP and analytes are mainly hydrogen bonding and π-
π complexation, but depending on the mobile phase system, other interactions such as inclusion 
complexation and steric interactions can be important.60 An investigation involving biologically 
active peptides used 42 peptides from 11 families, including angiotensin, bradykinin, dynorphin, 
enkephalin, and leucokinin.69 These were separated on the above-mentioned three macrocyclic 
glycopeptide stationary phases in RP HPLC using electrospray ionization-MS-compatible mobile 
phases. Single amino acid substitutions (including chiral residue substitution) were resolved. A 
series of enkephalin-related peptides with different numbers of D-residues have been separated 
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using this CSP.70 Those with three or four D-amino acids were most retained by the CSP column, 
with YdAGFdL eluted first among six enkephalin peptides (Figure 2.5).   
 Several ligand-exchange CSPs have been developed, such as those based on a cinchona 
alkaloid. Lindner and colleagues 71 achieved separation via interactions between the chiral 
selectors and analytes, including ionic attractions, hydrogen bonds, π-π interactions and steric 
interactions. A tert-butylcarbamoylquinine CSP was used to separate alanine peptide enantiomers 
and diastereomers. The four stereoisomers of Ala-Ala dipeptide were separated with four different 
N-terminal protections. In total, five different N-terminal protections (3,5-dinitrobenzoyl, 2,4-
dinitrophenyl, 3,5-dinitrobenzyloxycarbonyl, carbazole-9-carbonyl, and 9-
fluorenylmethoxycarbonyl) were examined in terms of their effects on elution order and 
selectivity. In their follow-up study comparing CSP-based columns with non-chiral RP columns 
for separating model peptides consisting of Ala oligomers, the cinchona alkaloid derivative-based 
CSPs demonstrated superior enantiomeric selectivity than diastereoselectivity.72 All 8 
stereoisomers of a tripeptide (Ala–Ala–Ala), and 9 out of 10 stereoisomers of a tetrapeptide (Ala–
Ala–Ala–Ala), could be successfully resolved using 2 combined steps.  
 Another unique category of CSP is the molecularly imprinted polymer (MIP). This type 
of CSP represents a small-molecule recognition system, produced using the target analyte as 
template.73 MIPs were first reported by Polyakov 74-76 in 1931, and are now used as a CSP in 
chiral separations, working in much the same way a receptor or an antibody recognizes its ligand 
or antigen. As one example, a non-covalent MIP produced against the template molecule N-Ac-L-
Phe-L-Trp-OMe was able to resolve it from the LD-, DL-, and DD-forms, with the template 
molecule retained longest.77   
 As this discussion indicates, because no specific material has been found to be 
universally applicable for all kinds of peptide separations, a variety of CSPs have been used in 
enantiomer and diastereomer analysis. While just a few have been discussed here, many others 
have been reported: cyclodextrins,78-79 polysaccharides,80 synthetic amino acid polymer,81 alpha-
chymotrypsin CSP,82 and Pirkle-type CSPs.83  
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Capillary Electrophoresis. CE is a small-volume separation approach with high separation 
efficiency, well suited to separating mass-limited samples such as endogenous peptides. Chiral 
separations use mobile phase additives added to the background electrolyte. Commonly used 
CMPAs include cyclodextrins, chiral ion pair complexes, chiral ligand-exchange complexes, and 
others. Because the selector is added to the electrolyte, one can easily optimize the additive 
composition and concentration, unlike a system that requires a new stationary phase. 
 Cyclodextrins are the most common additive employed in CE separations, sometimes 
used with other additives such as sodium dodecyl sulfate, changing the mode of separation to 
MEKC. Cyclodextrins are charged chiral molecules with a cavity of appropriate size to interact 
with an amino acid or peptide, thus modifying the peptide's electrophoretic mobility and allowing 
a separation. In one report of a peptide separation, diastereomers of aspartyl model dipeptides and 
tripeptides, including the isomeric iso-Asp-containing beta-peptides, were resolved in untreated 
fused-silica capillaries as well as polyacrylamide-coated capillaries using negatively charged 
cyclodextrins as chiral selectors.84 In another study, acylated Asp-Phe dipeptides, including α-L,L 
parent compound and three other potential Asp-containing stereoisomers (α-D,D, α-L,D and α-
D,L), as well as the four iso-Asp-containing stereoisomers (β-L,L, β-D,D, β-L,D and β-DL) were 
separated 85. Both neutral and charged cyclodextrins were used as CMPAs. Not surprisingly, 
buffer pH is an important parameter for optimizing these peptide separations. Oyler et al.86 
separated ten of Atosiban’s [1,1-(3-mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-
threonine-8-L- ornithine-oxytocin] diastereomers in free solution CE using 100 mM phosphate 
buffer with 5 mM γ-cyclodextrin. Without a chiral selector, these peptides do not separate. They 
compared this approach to hydrophilic interaction chromatography, and found that CE separates 
fewer peptides but demonstrated a different selectivity. Although endogenous peptide 
diastereomers have not been separated often, the low-volume advantages of CE were 
demonstrated by Sheeley et al.45 in measuring DAACPs from single invertebrate neurons. They 
developed a method using CE with laser-induced fluorescence (LIF) and γ-cyclodextrin as the 
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chiral selector to separate four D/L peptide pairs, and investigated the presence of NdWFa, a 
neuropeptide in Aplysia californica in single cells (Figure 2.6). 
 Several other chiral selectors discussed as CSPs for HPLC applications are used as 
additives in CE analyses. DL-Leu-DL-Phe and DL-Leu-DL-Leu were baseline separated using 
the crown ether (+)-18-crown-6-tetracarboxylic acid (18C6H4) as CMPA, based on different 
stabilities of the host-guest complexes formed.65 As another example, Riester et al.87 reported the 
successful resolution of eight isomers of YKW peptides by using crown ethers. In some cases, 
analytes can be derivatized with a reagent (or sometimes a chiral reagent) as this can result in an 
improved separation versus using chiral selectors alone. The ion-exchange type chiral selector 
tert-butylcarbamoylquinine was incorporated into the background electrolyte and functioned as 
chiral counter-ion in a stereoselective ion-pair CE system.88 After derivatizing with 3,5-
dinitrobenzoyl (DNB), 2,4-dinitrophenyl, or 3,5-dinitrobenzyloxycarbonyl, four stereoisomers of 
Ala-Ala were resolved and enantiomers of oligo-Ala peptides up to six amino acids long were 
also resolved. In a study by Wan and Blomberg,89 separation of chiral di- and tri-peptides 
derivatized with 9-fluorenylmethyl chloroformate were carried out by CE using vancomycin as a 
chiral selector. Four isomers of Leu-Leu and two isomers of Ala-Gly-Gly were separated, and 
three out of four isomers of Ala-Ala and Leu-Ala were resolved. 
 
Micellar Electrokinetic Chromatography. By adding surfactants into the background electrolyte, 
CE can be operated in a different mode with a chromatographic principle, known as MEKC. This 
mode is not as often used for DAACP/LAACP applications. The examples mentioned here 
mainly include the use of derivatized peptides. Wan et al.90 reported the separation of nine 
peptides with γ-cyclodextrin as the chiral selector. These peptides were derivatized with 9-
fluorenylmethyl chloroformate and subjected to MEKC separations. Two other peptides, Leu-Ala 
and Leu-Leu, were separated with β-cyclodextrin after derivatization. With the use of surfactants, 
separation based on both chiral selectivity and hydrophobicity occurred, resulting in a separation 
power that chiral selectors alone could not have achieved. In their later work, this same group 
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evaluated the concentration of teicoplanin and acetonitrile on the resolution and retention time of 
di- and tri-peptide separations.90 
 
Capillary Electrochromatography. Interestingly, the roles of LC and CE in chiral separations are 
distinct and yet somewhat complementary to each other. CEC can be considered a hybrid of these 
approaches, as it contains features of both LC and CE and so should be mentioned. In one report, 
the chiral peptide separation was achieved using a capillary packed with teicoplanin aglycone as a 
CSP.91 The diastereomeric dipeptides and tripeptides investigated were baseline-resolved. For 
these peptides, RP separations worked well, with the organic modifier having an important impact 
on the separation. 
 
2.4.3 Mass Spectrometry 
While MS can be interfaced with LC and CE separations, the ability to separate DAACPS from 
LAACPs is based on the differences in elution time offered by the separation. Can MS be used to 
characterize DAACPs directly? After all, MS is perhaps the detector of choice for peptide 
characterization as it allows structural characterization of the peptide, including most PTMs and 
sequences. How does one use MS to determine the chirality of an amino acid residue? Several 
studies have shown that differences in the chemical properties of two diastereomers can be 
detected by monitoring the stability of complexes formed with chiral selectors, and that tandem-
MS provides different fragmentation results based on the chirality of the amino acid residues.  
 Perhaps the most obvious approach is to use the same chiral selectors that maximally 
interact with the peptides during a separation for MS. Chiral recognition with the help of selectors 
usually depends on noncovalent forces such as hydrogen bonds and van der Waals forces that 
form between the analyte and chiral selectors. Initial work used crown ethers with fast atom 
bombardment as the ionization approach,92 and this has been extended to electrospray ionization 
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(ESI) 92 and matrix-assister laser desorption/ionization.93 Specifically, Jorgensen et al.94 used 
vancomycin with ESI on a triple-quadrupole instrument. The complex intensities of the (L,D,D)- 
and (L,L,L)-stereoisomers of diacetyl-Lys-Ala-Ala, the latter being isotopically labeled, were 
monitored by single-stage MS, and selective binding of vancomycin to the (L,D,D)-isomer was 
observed. This result was in good agreement with those from solution phase experiments. A later 
report used antibiotics with CID to investigate complexes of the antibiotics with tripeptides.95 
This work demonstrated a loss of specific binding between the antibiotics and the peptides when 
the two D-Ala residues located at the C-terminus were replaced with their L-configured isomers. 
 At times referred to as the kinetic method, exchange reactions have been used to monitor 
the stability of analyte-chiral selector complexes. This approach helped to discriminate four 
enantiomers of Ser-His-OMe, with a hydroxyl group and an imidazole group in the side chain 96 
(Figure 2.7). Two analyte enantiomers form complexes with copper chloride and a chiral 
reference compound (denoted as ref* in the figure) in solution, and competitive CID occurs to 
form the dimeric complexes by loss of ref* or the analyte, respectively. The potentially different 
stabilities of the diastereomeric ions are reflected by different abundances of the fragment ions 
relative to that of a common fragment. Experimental abundance ratios were used to determine the 
enantiomeric composition of the analyte, provided a calibration curve is obtained beforehand. 
Lagarrigue et al.97 used CuII and FeII as transition metal ions to differentiate the diastereomeric 
pentapeptides YAGFL, YDAGFL and YDAGFDL by ESI-ion trap MS. Dissociation rate 
constants under low-energy CID process of the complexes formed between peptides and metal 
ions are dependent on their stabilities resulting from different steric interactions.  
 It is also possible to characterize DAACPs and other peptides without using chiral 
selectors, usually by examining the molecular fragmentation in tandem-MS spectra. Intrinsic 
differences among diastereomers are the basis for this type of characterization. Some pioneer 
studies include Mammoliti et al.,98 who demonstrated that Z-blocked Phe-Phe and Ala-Phe 
diastereomers differed in their decarboxylation behaviors through competing pathways. The 
different kinetic energy released from these decarboxylation reactions allowed the diastereomers 
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to be discriminated from each other. Using unimolecular decomposition, another study showed 
that different diastereomers had different product ion abundances.99  
 Tsunematsu et al.100 assessed the differentiation of diastereomers of BOC-protected Pro-
Pro by studying the sodium adduct ions with both single-stage and tandem MS. Adams et al.101 
distinguished diastereomers of Trp-cage peptide (NLYIQWLKDGGPSSGRPPPS) by electron 
capture dissociation. The fragmentation pattern reflects differences in the stability of the gas-
phase tertiary protein structure with a D-amino acid substitution. The chiral selectivity was 
diminished at higher temperature when the tertiary structure was degraded, and was also reduced 
at higher charge states where ionic interactions largely destroyed the neutral hydrogen bonding 
needed for chiral recognition. Tandem MS experiments using CID did not allow differentiation 
between diastereomers using fragment ratios; however, substantially different stabilities of the 
parent ions were noted. The same group completed another interesting investigation by adapting 
the kinetic method to quantify the differences between fragmentation patterns of stereoisomeric 
peptides by measuring fragment ion abundances 102 (Figure 2.8). Dermorphin and related peptides 
were discriminated and quantitatively measured.  
 Five epimers of the pentapeptide, GLSFA, were discriminated by their different 
collisionally activated dissociation (CAD) patterns. Ratios of fragment ion abundances between 
stereoisomers have been measured 103 and the values were as high as 3.8, meaning the 
configuration of stereoisomer pairs was dramatically different. Stereochemical effects were also 
demonstrated using ω-agatoxins IVB and -C, and diprotonated peptide LVFFAEDVGSNK, a 
tryptic fragment from the amyloid β-protein. We expect such approaches to become more 
common. 
 
2.4.4 Nuclear Magnetic Resonance  
NMR can determine the three dimensional structure of a peptide and so can be used to resolve the 
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chirality of peptide residues. Typically used to study molecular interactions between analytes such 
as peptides and chiral selectors,104-106 it does not appear that NMR has been used for DAACP 
peptide discovery as yet, partially because of its intrinsic low sensitivity compared to the 
separations- and MS-based approaches. It also has been applied to studying peptide-receptor 
interactions 107 and will become an indispensable tool to examine the differences in interactions 
between an endogenous DAACP and an LAACP with their cognate receptors. As one example of 
the use of NMR, achatin-I (GdFAD), isolated from A. fulica, was found to have different 
chromatographic behavior from its all-L isomer. An 1H-NMR spectral study demonstrated the 
points of interaction as the α-methine proton of the phenylalanine with the α-methane proton and 
the methyl protons of alanine in achatin-I appearing upfield from the L-isomer. In another 
interesting study from the peptide toxin field,23 an NMR experiment demonstrated the necessity 
of having a D-Phe13 in the conotoxin peptide, conomarphin, for forming a tight loop in the 
middle of the peptide. The toxin counterpart with L-Phe13 did not form this loop, perhaps 
indicating the reason why a D-Phe is required to obtain the specific functions of this peptide.  
 
2.4.5 Peptide Digestion  
Acid Hydrolyzation. In multiple instances of DAACP discovery, acid hydrolysis followed by 
derivatization and separation is common because the separation of amino acid enantiomers is a 
relatively mature technique. The limited number of possible amino acids makes the analysis of 
peptide hydrolysates more convenient. As a classic example, to confirm that [D-Leu2]deltorphin 
was a DAACP, the peptide was first hydrolyzed, amino acids derivatized with a chiral reagent, 1-
fluoro-2,4-dinitro-5-L-alanine and separated by RP-HPLC, and configuration of each residue 
determined.8, 108  In a study focusing on beta-amyloid peptides from Alzheimer's disease patients, 
the peptides were digested, the resulting amino acids derivatized with the chiral reagent (+)- or (-
)-1-(9-anthryl)-2-propyl chloroformate, and subsequently separated using MEKC.109 The high 
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separation efficiency of the MEKC-LIF system, yielding approximately a million theoretical 
plates/m for most amino acids, facilitated the simultaneous chiral determination of nine amino 
acids. Samples analyzed include 1-40 beta-amyloid peptides, in vitro precipitated beta-amyloid 
fibrils, and human senile plaque samples. As another example, Liu et al.110 derivatized peptides 
and amino acids with 4-(3-isothiocyanatopyrrolidinl-yl)-7-nitro-2,1,3-benzoxadiazole [R-(-)- or 
S-(+)-NBD-PyNCS] and characterized the resulting diastereomeric derivatives using CE; they 
characterized the D-amino acids in the peptide gramicidin D after applied acid hydrolysis. 
 Amino acid analysis after acid hydrolysis itself does not generate sequence information 
for the peptides; therefore, sequencing approaches such as Edman degradation and tandem-MS 
are usually employed. Simultaneous sequencing combines Edman degradation methods and a 
derivatizing reagent; thus, residues freed from the peptide can be immediately converted to 
identifiable units.111 Using this technique, a group of hydrophobic peptides discovered in B. 
variegata were found to contain a D-alloisoleucine residue in the second position.11 Separation of 
TZ-amino acids generated in an Edman procedure can be separated on a CSP (-cyclodextrin); 
chiral Edman reagents were introduced by Toyo’oka and Liu in 1995.112 Kurosu et al.113 
demonstrated optical resolution of phenylthiohydantoin amino acids by CE and identification of 
the phenylthiohydantoin-D-amino acid residue of [D-Ala2]-methionine enkephalin.  
 
Enzyme Digestion. DAACPs are obviously functionally important, either because they have 
different receptor binding or a different lifetime due to a greater resistance to common peptidases. 
One can turn these biologically important differences into a method of characterizing the 
DAACPs. In fact, the enzymatic approach is among the earliest used for determining DAACPs. 
 Lipmann et al.5 developed the enzymatic method in 1940 to identify the presence of D-
amino acids in a small sample. In this pioneering work, they used D-amino acid oxidase to act on 
hydrolysates because this enzyme selectively digests D-amino acids instead of L-residues; they 
measured oxygen consumption and ammonia production to determine the substrate configuration. 
This method was later employed by Montecucchi et al.6 in discovering dermorphin in 1981 and 
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Erspamer et al.10 in finding deltorphins I and II. Specifically, the presence of D-alanine in [D-
Ala2]deltorphins (YdAFD, YdAFE), isolated from skin extracts of Phyllomedusa bicolor, was 
demonstrated by using D-amino acid oxidase on acid hydrolysates of the peptides; the 
disappearance of this amino acid species indicated it is in the D-form.10 
 Another enzyme that has been used to assist DAACP discovery is aminopeptidase M. 
This enzyme cleaves N-terminal L-amino acids off peptides but won’t digest D-amino acids. In a 
recent study, Ewing et al. 114 used this enzyme to screen for DAACPs by taking a nervous system 
extract, and dividing it into two samples, one of which was digested with the enzyme; both 
fractions were then subject to LC-MS (Figure 2.9). This study observed that peptides that were 
not digested were more likely to be DAACPs, and those that disappeared after exposure to the 
enzyme were more likely to be composed solely of L-amino acids. As a proof of concept, after 
digestion of the abdominal ganglia extract of A. californica, the known DAACP, NdWFa, was 
characterized. Several additional peptides were shown to be resistant to the enzymatic digestion; 
it will be interesting to see if these are unknown DAACPs.   
 
2.5 FUTURE DIRECTIONS  
 
Peptidomics, the global characterization of peptides, whether toxins, neuropeptides or even 
serum-peptides, is an area that is receiving greater and greater attention. These studies aim to 
characterize the peptide complement, including PTMs, in complex samples such as a brain tissue. 
With the addition of an L-to-D switch in the configuration of an amino acid in a peptide now 
considered as a possible PTM, achieving complete characterization of endogenous peptides is a 
more complex endeavor. Certainly, new methods are required to accomplish such measurements 
and represent one future direction of peptidomic research. As outlined in this review, a variety of 
analytical techniques are currently capable of separating and characterizing the configuration of 
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amino acids in a peptide. To date, however, most approaches have worked with synthetic peptides 
and relatively simple mixtures. We expect that further refinements will continue, and that 
approaches will be developed that can handle hundreds to thousands of peptides. Some 
approaches will be survey-based, enabling one to determine which peptides in a mixture are 
putative DAACPs, and others will allow preselected peptides to be evaluated. Only by 
implementing both approaches will questions on the prevalence and function of this elusive PTM 
be addressed. We certainly expect the range of analytical methods used to evaluate chirality to 
expand as improved separations and new enzymatic approaches are reported.  Hopefully, in the 
future, the enzymes responsible for these transformations will be known, allowing specific tissues 
containing the appropriate enzymes to be targeted for DAACP characterization.  
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FIGURES AND TABLES 
 
 
 
Figure 2.1. Ball-and-stick illustration of an L-amino acid (L-alanine) with -COOH, -NH2 and -R 
groups arranged clockwise around the carbon chiral center when viewing with -H away from the 
center. Carbon atoms (grey), nitrogen (blue), hydrogen (white), and oxygen (red). The D-amino 
acid has the counterclockwise arrangement around the chiral center. Reused with kind permission 
from Springer Science+Business Media.1  
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Figure 2.2. DAACPs have been found in a surprising range of species in Metazoa, for example 
(top row), sea slug Aplysia californica (photo by Genny Anderson),115 platypus Ornithorhynchus 
anatinu,116 (bottom row) lobster Homarus americanus,117 funnel-web spider Agelenopsis aperta 
(photo courtesy of Spider Pharm. Inc),118 and South American tree frog Phyllomedusa 
sauvagei.119 Reused with kind permission from Springer Science+Business Media.1  
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Figure 2.3. Elution profile of an active fraction isolated from skin secretions of Phyllomedusa 
sauvagei on a Supelcosil LC18DB column without chiral selectors. Synthetic deltorphin 
diastereomers, [L-Met2]deltorphin (solid circle) and deltorphin (solid square), were used as 
reference standards (dashed curves). The active fraction (indicated by the height of the lower 
black bars underneath) has the same elution time with deltorphin.  Reproduced with permission 
from Elsevier.7 Reused with kind permission from Springer Science+Business Media.1  
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Figure 2.4. (A) Crown ether (-)-(18-Crown-6)-tetracarboxylic acid. (B) HPLC separation of Ala-
Phe stereoisomers on a (-)-(18-Crown-6)-tetracarboxylic acid-based column. Interaction between 
protonated amine groups in peptides and oxygen atoms lining the inner surface of the crown ether 
molecule is the basis of chiral selectivity. 10 mM sulfuric acid in 70% methanol-water was used 
as mobile phase to facilitate protonation of amine groups. Adapted with permission from Wiley-
VCH Verlag GmbH & Co. KGaA.63 Reused with kind permission from Springer 
Science+Business Media.1  
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Figure 2.5. HPLC separations of enkephalin diastereomers on (A) teicoplanin stationary phase 
compared to (B) C18 stationary phases. The arrow in (A) indicates the beginning of a step 
gradient (from isocratic 78% ACN/22% 3 mM ammonium acetate to 70% ACN/30% 0.1% (v/v) 
formic acid in water at 36 min) found necessary to decrease the elution time of E3 and E4. 
Arrows in (B) indicate the linear gradient in between (80% 13 mM ammonium acetate/20% ACN 
at 10 min to 30% ACN at 45min). These two stationary phases are different in selectivity and thus 
peptides have different retention orders. Enantiomeric pair E0 and E4 and diastereomeric pair E1a 
and E3were not separated on the non-chiral column, whereas teicoplanin-based CSP was able to 
resolve every peptide. Adapted with permission from Springer.70  Reused with kind permission 
from Springer Science+Business Media.1  
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Figure 2.6. Characterization of NdWFa using CE in a single Aplysia ventral abdominal neuron. 
(A) Representative electropherogram obtained from a single ventral abdominal neuron. (B) CE 
electropherogram of a ventral abdominal neuron spiked with synthetic NdWFa standard. (C) 
Electropherogram of a ventral abdominal neuron spiked with synthetic NWFa standard, which 
migrates faster than the endogenous NdWFa peak. The measurement has been repeated three 
times on different peptidergic neurons. Reproduced with permission from the Royal Society of 
Chemistry.45 Reused with kind permission from Springer Science+Business Media.1  
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Figure 2.7. The top scheme illustrates the principle of kinetic method and the bottom multipart 
figure shows the CID fragmentation patterns of [CuII(A)(ref*)2-H]+ (m/z 771), with the ref* 
molecule being Ala-His dipeptide, and various analytes: (A) A = L-Ser-L-His-OMe; (B) D-Ser-L-
His-OMe; (C) L-Ser-D-His-OMe; and (D) D-Ser-D-His-OMe. Patterns of competitive collision 
for each stereoisomeric complex depend on their respective stabilities, therefore, the abundance 
ratio Re=[CuII(A)(ref*)-H]+ / [CuII(ref*)2-H]+ of different complexes can be used to measure 
the relative abundance of stereoisomers when a calibration curve is available. Top panel120 and 
bottom panel96 are adapted with permission from Wiley-Blackwell. Reused with kind permission 
from Springer Science+Business Media.1  
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Figure 2.8. (cont. on next page) 
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Figure 2.8. (A) Comparison of CAD fragmentation patterns generated from dermorphins, all-L 
form (top) and D-Ala2 form (bottom). Relative abundance of b5+ and y5+ fragment ions, shown 
in upper right insets, is used for chiral composition determination. RL(ratio b5/y5 for L-form) is 
about 2.3 and RD is about 4.8 at 50 arbitrary CAD excitation units. (B) The ratios of the chirality-
reporting fragment ion pairs b5/y5 as a function of CAD excitation intensities in arbitrary units. 
The chiral recognition factor Rchiral (ratio RD/RL) is relatively constant at different excitation 
levels. Adapted with permission from the American Chemical Society.102 Reused with kind 
permission from Springer Science+Business Media.1  
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Figure 2.9. Characterization of DAACPs from a complex mixture of peptides using an enzymatic 
digestion method. Aplysia abdominal ganglia were used to make extract. (A) and (B) are LC base 
peak chromatograms showing 465–466 m/z range, which matches the NWFa/NdWFa peak, 
without enzyme treatment (A) or with 1.0 units of mAAP treatment (B). (C) and (D) are 
corresponding MS spectra showing NWFa/NdWFa peaks. Enzymatic treatment facilitated 
detection of otherwise barely detectable peptides. Reproduced with permission from the 
American Chemical Society.114 Reused with kind permission from Springer Science+Business 
Media.1  
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Table 2.1. More than 30 DAACPs have been discovered in the last 38 years.  
 
Source Peptide [Reference] Sequence1 Species 
land mollusc Achatina 
neuropeptides 
Achatin I 12 GdFAD Achatina fulica 
Fulicin 44 FdNEFVa   Achatina fulica 
Fulyal 13 YdAEFLa Achatina fulica 
Conus toxins 
Contryphan 15  GCOdWEPWCa Conus radiatus 
Des-[Gly 1]contryphan-R 15 COdWEPWCa Conus radiatus 
Contryphan-P 17 GCPdWDPWCa Conus purpurascens 
Contryphan-Sm 17 GCOdWQPWCa Conus stercusmuscarum 
Bromocontryphan-R 16 GCOdWEPW(6-bromo-W)Ca Conus radiatus 
Contryphan-R 17 GCOdWEPWCa(disulfide bond) Conus radiatus 
Leu-Contryphan-P 18 GCVdLLPWC  Conus purpurascens 
Leu-contryphan-Tx 121 CVdLYPWCa Conus textile 
Contryphan-Tx 121 GCOdWQPYCa Conus textile 
R11a (I-superfamily) 20 dF at 44th in 46 a.a. Conus radiatus 
R11b,c 19 dF at 44th in 46 a.a.,dL at 42nd in 44 a.a. Conus radiatus 
Conomap-Vt 22 AdFVKGSAQRVAHGY Conus vitulinus 
Conomarphin (M super family) 23 DWEYHAHPKONSdFWT Conus marmoreus 
Conophan 24 AOANSdVWS Conus gladiator 
marine molluscan 
peptides 
NdWFa 14 NdWFa Aplysia kurodai 
Mytilus-FFRFamide 26 AdLAGDHFFRFa    Mytilus edulis 
Ocp-1/4 25 GdFGD/GdSWD  Octopus minor  
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Table 2.1. (cont.) 
crustacean hyperglycemic 
hormone 
CHHA, cHHB 27 pGlu-VdFDQACK Homarus americanus 
Prc CHH-II 28 dF at 3rd in 72 a.a. Procambarus clarkii(crayfish) 
spider venom peptide IVB (ω-agatoxin-TK) 29, 122 dS at 46th 46 a.a. Agelenopsis aperta 
frog skin toxin 
Dermorphin 6 YdAFGYPSa Phyllomedusa sauvagei 
Deltorphin(met) 7 YdMFHLMDa Phyllomedusa sauvagei 
Deltorphin(leu) 8 YdLFADVASTIGDFFHSIa Phyllomedusa burmeisteri 
Deltorphin A (Dermenkephalin) 9 YdMFHLMDa Phyllomedusa sauvagei 
Deltorphins I (B) II (C) (ala) 10 YdAFD(E)VVGa    Phyllomedusa bicolor 
Bombinin (H3-H5) 11 D-aIle at 2nd in 21 a.a. Bombina variegata 
platypus peptides 
Platypus peptide (OvCNPb) 30 LdLHDHPNPRKYKPANKKGLSKGCFGLKLDRIGSTSGLGC 
Ornithorhynchus anatinus  
DLP-2 31 dM at 2nd in 42 a.a. Ornithorhynchus anatinus  
1Each amino acid is represented by its one letter abbreviation, the letter following a “d” indicates that amino acid is in D-form, and “a” means 
amidation of the C-terminal residue. Reused with kind permission from Springer Science+Business Media.1 
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CHAPTER 3  
 
DISTINGUISHING D-AMINO ACID-CONTAINING 
NEUROPEPTIDES IN THE GAS PHASE  
Notes and Acknowledgements 
This chapter is reproduced with permission from L. Bai, E. V. Romanova, J. V. Sweedler, 
Distinguishing endogenous D-amino acid-containing neuropeptides in individual neurons using 
tandem mass spectrometry. Anal. Chem. 2011, 83. 2794-800, DOI: 10.1021/ac200142m 
(Copyright 2010 American Chemical Society).1 This chapter highlights a technique using matrix-
assisted laser desorption ionization time-of-flight/time-of-flight (MALDI-TOF/TOF) mass 
spectrometry (MS) to distinguish neuropeptides with the second residue isomerized to their D-
isoforms. Dr. Elena V. Romanova performed single-cell sampling experiments to locate the 
NWFa/NdWFa-containing neurons from Aplysia californica. E. V. R. and Xiying Wang assisted 
with animal dissection. Karen Avenatti, Dr. Peter M. Yau and Dr. Brian S. Imai from the 
Biotechnology Center synthesized peptide standards. This work is supported by NSF CHE-11705 
and NIH through R01 NS31609 (to JVS).  
 
3.1 ABSTRACT 
 
RNA-based protein synthesis produces L-amino acid-containing proteins and peptides. D-amino 
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acid-containing peptides (DAACPs) can be generated from L-amino acid peptides via post-
translational modification. In the nervous system, the conformational change of a single L-amino 
acid in a peptide to its D-form results in altered bioactivity, with some DAACPs having orders-
of-magnitude enhanced efficacy. However, this modification is often overlooked when 
characterizing endogenous peptides. Here, with the use of matrix-assisted laser desorption 
ionization (MALDI) time-of-flight (TOF)/TOF mass spectrometry, neuropeptides that have the 
second residue isomerized to the D-isoform are distinguished from their L-epimers via 
differences in the relative amounts of specific fragment ions during tandem MS. With the 
appropriate fragment ions chosen, and in some cases with the use of metal adducts, epimer 
discrimination is optimized. Specifically, the cardioexcitatory peptide Asn-DTrp-Phe-amide 
(NdWFa) was assayed directly from neurons isolated from the sea slug Aplysia californica; the 
fraction of the peptide with the second residue (W) in the D- versus L-form was 90±10%. We 
demonstrate that this approach is well suited for confirming DAACPs directly from cells and 
tissue, advancing our understanding of the L to D modification and the role it plays in cell-to-cell 
signaling. 
 
3.2 INTRODUCTION 
 
Neuropeptides act as cell-to-cell signaling molecules and perform important roles in the central 
nervous system in animals. They are generated via the processing of larger precursor proteins into 
biologically active peptides and their function is often dependent on chemical modifications.2-3 
One of the more unusual post-translational modifications (PTMs) in neuropeptides is the 
isomerization of an L-amino acid residue into its D-form.4 
 D-amino acid-containing peptides (DAACPs) share the same sequence with their all-L 
isomers, but in many cases, the D-amino acids confer distinct and at times, dramatically enhanced 
receptor binding affinity.5-6 Consequently, the modification is sometimes a requisite for the 
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induction of physiological effects. For example, NdWFa, a cardioexcitatory peptide first isolated 
from Aplysia kurodai, was found to be highly active in the modified form, but NWFa only 
induces minimal effects.7 As another example, achatin-I (Gly-DPhe-Ala-Asp), isolated from the 
African giant land snail Achatina fulica, demonstrated potent neuroexcitatory effects, while the 
all-L-form isomer achatin-II (Gly-Phe-Ala-Asp) lacked significant activity.8 How is this 
enhancement possible? The isomerization event changes secondary structure,9-11 and in longer 
peptides, even disrupts tertiary structures.12 Moreover, because binding affinity depends on shape, 
and is also dependent on electronic interactions and hydrogen bonding between the peptide and 
the receptor, changes in shape can dramatically shift the bioactivity of these cell-cell signaling 
molecules.  
Over the last three decades, multiple DAACPs have been reported in mollusks, such as 
NdWFa, achatin-I and its homolog in octopus, ocp-1 and ocp-4,13 fulicin (FdNEFVa) and fulyal 
(YdAEFLa), with the latter two peptides from the fulicin gene-related peptide precursor.8, 14-15 In 
total, ~30 DAACPs (including hormones and antimicrobial peptides) have been found in a variety 
of species.7, 13, 16-35 In several cases, the PTM has been created by a peptidylaminoacyl-L/D-
isomerase. Several isomerases have been reported, including enzymes from the funnel web spider 
Agelenopsis aperta,36 the frog species Bombina variegate and Bombina orientalis,37 and the 
primitive mammal, the platypus.38 These enzymes do not share the same catalytic mechanisms, 
and more interestingly, the preferred site of isomerization is distinct. The enzyme(s) responsible 
for the formation of DAACP in several molluskan species (e.g., NdWFa, FGRPs, achatin) are not 
known, but they share a strikingly conserved activity in the formation of these specific DAACPs; 
the second position from the N-terminal is the amino acid that is isomerized. A separate class of 
naturally occurring D-amino acids in peptides is spontaneous racemization, for example, a D-Ser 
residue in the beta-amyloid protein [D-Ser26]Aβ1-40 is generated in an age-dependent process. 
This non-toxic form is processed by a protease to form the more problematic peptide [D-
Ser26]Aβ25-35/40, which may be related to the transition of the soluble Aβ to the pathological 
fibrillar form.39 
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How many neuropeptides contain a D-amino acid residue but have yet to be discovered 
due to the lack of a sensitive assay? Questions about how DAACPs function cannot be answered 
unless there is an efficient method to characterize them. Unfortunately, conventional sequencing 
techniques such as Edman degradation and mass spectrometry (MS) do not distinguish D- from L-
amino acids, raising the possibility that previously “characterized” peptides may have been tested 
for bioactivity on the non-physiological, all-L-amino acid-containing forms. Therefore, in order to 
achieve complete characterization of a novel peptide, techniques that allow diastereomeric 
characterization of the amino acids in peptides are required, especially in cases where the L-form 
has not been shown to have robust activity. 
How are unidentified DAACPs characterized? While MS is the most common approach 
for characterizing an unknown peptide,40-41 because this PTM has no associated mass change, 
improved approaches are needed. One option is enzymatic screening, which uses specific 
enzymes to selectively degrade peptides that contain only L-amino acids.42 An enzyme-aided 
screening method, when combined with MS, can be used to identify peptides containing a D-
amino acid near the N-terminal, even from a complex mixture. The advantage of this type of 
screening approach is that standards are not required; note however, that other peptide 
modifications can cause false positives. Confirming that a peptide contains a D-residue entails 
additional experimental steps, and often requires L- and D-amino acid-containing peptide 
standards to accomplish. One of the more interesting MS-based techniques used to distinguish 
diastereomers relies on the stability of complexes formed between an added metal species and the 
diastereomers, known as the kinetic method.43 The semi-stable complexes formed with the 
peptide isomers have different thermochemical properties that lead to different branched 
fragmentation profiles, thereby enabling discrimination.  
These approaches can be extended by application of direct tandem MS (MS/MS) methods 
to investigate the protonated peptides. By measuring the differential fragmentation patterns, the 
diastereomers can be discriminated. Relatively soft ionization methods such as electrospray 
ionization (ESI) can allow enough solution-phase structure to carry into the gas phase to allow 
 59 
 
such discrimination.44 Recently, Adams et al.45 reported using ESI-Fourier transform MS with 
electron capture dissociation to distinguish and quantify DAACPs and proteins with a limit of 
detection of 1%; later this method was extended to MALDI MS by Sachon el al.46 In the latter 
work, two short peptides were studied and discrimination made by measuring the abundance of 
corresponding fragment ions generated from the different epimers; for DAACPs with a 
substitution of the 2nd residue, N-terminal acetylation was introduced to enable the distinction. 
These methods serve as downstream approaches to confirm the DAACP candidates, but to date 
have used only synthetic peptides.  
For this study, we adapted the MALDI MS method described above,46 combining it with 
the direct MALDI measurement of complex mixtures of peptides in individual and small numbers 
of neurons.47-48 Cells were deposited directly onto a MALDI target and the DAACPs 
distinguished and quantified using collision-induced dissociation (CID) MS/MS. We validated 
this approach with known molluskan DAACPs. Using a working curve derived from standards, 
we characterized the fractions of NWFa and NdWFa within single cells—obtaining amounts 
consistent with prior reports—and demonstrated the ability to discriminate other putative Aplysia 
DAACPs. For those peptides where the two isomers fragmented similarly for the measured 
fragments, the use of various additives was shown to enhance chiral discrimination. Thus, this 
approach appears to be general, at least for all of the peptides tested here. 
 
3.3 EXPERIMENTAL SECTION 
 
Materials. Synthetic peptides: NWFa, YAEFLa, GFAD, GFFD, FMRFa, and the corresponding 
four analogs with D-amino acids in the second position (Table 3.1), were synthesized by the 
Protein Sciences Facility, University of Illinois at Urbana-Champaign. Chemicals and reagents: 
Water was purified from a Milli-Q system (Millipore, Bedford, MA); the antibiotics, 2,5-
dihydroxybenzoic acid (DHB), NaCl, KCl, CaCl2, MgCl2, CoCl2, MgSO4, HEPES, and 
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acetonitrile (ACN) containing 0.01% trifluoroacetic acid (TFA), were obtained from Sigma-
Aldrich (St. Louis, MO).  
 
Animals. Aplysia californica (120–170 g) were purchased from the University of Miami/NIH 
National Resource for Aplysia and kept in an aquarium containing aerated and filtered artificial 
seawater (Instant Ocean, Aquarium Systems Inc., Mentor, OH) at around 14 °C until used. Prior 
to dissection, animals were anesthetized by injection of isotonic MgCl2 (30 to 50% of body 
weight) into the body cavity.  
 
Neuron Isolation. The abdominal ganglia were dissected and incubated in artificial sea water 
(ASW: 460 mM NaCl, 10 mM KCl, 10 mM CaCl2, 22 mM MgCl2, 6 mM MgSO4, and 10 mM 
HEPES, pH 7.8) supplemented with antibiotics (penicillin G, gentamycin and streptomycin) and 
containing 1% (w/v) protease (Type IX: Bacterial; Sigma-Aldrich) at 32 °C for 45 min to loosen 
the connective tissue sheath. Following a 1–3 h rinse in ASW with antibiotics to remove the bulk 
of the protease, the ganglia were stretched onto a silicone elastomer (Sylgard, Dow Corning, 
Midland, MI) layer in a petri dish containing 3–4 mL of the ASW-antibiotic medium using 0.15 
mm diameter tungsten needles (WPI, Sarasota, FL) and connective tissue was surgically removed 
to expose neurons.  
Clusters of peptidergic neurons from individual A. californica containing N(d/l)WFa 
were identified according to their position, size, and pigmentation.49-50 Isolated neuron clusters 
were briefly rinsed in Milli-Q water to remove excess salts and ASW before depositing onto the 
MALDI target. Excess liquid was aspirated from the target and spot-to-spot cell transfers were 
performed for sampling of individual neurons as described previously.51 Between 0.2–0.4 µL of 
10 mg/mL DHB matrix was applied by the dried droplet method over the lysed cells. Ten animals 
were tested (biological replicates), and at least three technical replicates were made from each 
biological sample.  
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MALDI TOF/TOF MS Analysis. MS measurements were performed using an UltrafleXtreme 
MALDI time-of-flight (TOF)/TOF mass spectrometer (Bruker Daltonics, Billerica, MA) in 
positive-ion reflector mode. MS/MS measurements were performed in “LIFT” mode with CID 
turned on. Collision was performed with argon gas, creating a source pressure of 6 × 10-6 mbar, 
and the collisional energy was typically set to 27 keV, including a potential raise in the “LIFT” 
chamber. External peptide standards were used for calibration of the MS and MS/MS in the low 
mass range.  
For the synthetic peptides, 0.7 μL of 1 mg/mL of each was dissolved in water, deposited 
on the target, and mixed 1:1 (v/v) with matrix: 10 mg/mL of DHB in 50% ACN with 0.01% TFA. 
In some experiments, 0.5 μL of 1 mM CoCl2 was co-spotted with sample and matrix in order to 
form metal-peptide complexes. For each synthetic peptide sample, six replicate spots were 
characterized. For each replicate, the spectrum was an average of 5,000 laser pulses. The same 
instrument settings were used for the synthetic peptide samples that included mixtures of the D- 
and L-standards.  For calibration curve plotting, the D-epimer mole fraction was incremented in 
20% steps, and data collection was the same as with the pure isomers. For the single-cell 
measurements, conditions were the same, except that laser intensity was adjusted to observe 
peaks with a signal-to-noise ratio higher than 100 but not saturated; this value was kept consistent 
across the cell samples from each animal (with n = 10).  
The MS/MS spectra were analyzed using the FlexAnalysis and Biotools software 
packages (Bruker Daltonics). Statistics was performed with intensity/area values exported from 
FlexAnalysis. Statistical calculations, including mean and standard deviation for bar charts and 
calibration curves, were performed using Microsoft Excel 2010. To compare fragmentation 
patterns between two epimers, intensity values for each fragment ion were normalized to the sum 
of all major fragment ions produced from the particular sample spot (except for results from 
metal adducts, which were normalized to the most intense peak as the metal adduct example 
contained large numbers of low intensity peaks).  The observed fragment ion peaks were mass 
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matched to predicted fragment ions using Protein Prospector 
(http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msproduct).   
 
3.4 RESULTS AND DISCUSSION 
 
Our goal was to determine if the neuropeptides known to contain D-amino acids have enough 
differences in their fragmentation patterns to enable the peptide fraction in each form to be 
characterized. While ESI MS is normally considered to be more reproducible, we use MALDI 
TOF/TOF MS here because of its compatibility with direct cell and tissue measurements, thereby 
enabling smaller-volume neuropeptide characterization.40, 52-53 
The D-amino acid-containing neuropeptides NdWFa, YdAEFLa, and GdFAD previously 
reported from animal tissues, and another two short peptides, GdFFD and FdMRFa, and their five 
respective L-epimers were used for MS/MS measurements. These peptides yield fragment ions, 
with b- and y- being the major types; the product ions resulting from further water losses can be 
detected as well (see Table 1, with additional supporting data presented in the Supporting 
Information).  The peak intensity and area value of each major fragment ion were both measured 
and the results did not differ significantly (data not shown); therefore, the peak intensity 
measurements were used for analyses.   
A reasonable reproducibility of the peak intensity measurements allows comparison 
between epimers; however, we found that the intensities of product ions can vary significantly 
across six replicate spots. In order to improve run-to-run consistency, instrumental parameters, 
including laser fluence, remained unchanged throughout the samples tested. In addition, all 
fragment ion intensities were normalized, either to the sum of product ions generated from the 
respective replicate, or to the most intense peak (the latter was done in the case of the metal 
adducts, where there were large numbers of low intensity product ions). With this normalization 
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procedure, a small standard deviation was observed (less than 1% relative standard deviation for 
major fragment ions), allowing clear discrimination between epimers. 
For the five peptide pairs tested, pure D- and L-form peptides demonstrated significant 
stereochemical effects that allowed discrimination of their fragment ion fingerprints (Figure 3.3, 
with F(d/l)MRFa shown in Figure 3.4). Not surprisingly, this technique demonstrated differing 
abilities in characterizing some pairs over others, reflected in the Rchiral values of each pair, where 
Rchiral represents the ratio of RD and RL, with each being the ratio of a pair of chirality-reporting 
fragment ions for the D- and L-epimer, respectively. While one could use the entire spectra to 
distinguish the two forms, here we determined the specific fragment ion(s) that were most useful 
for this discrimination. The relative quantification of the differentially generated fragments, as 
shown in the bar charts (Figure 3.3), led to the identification of indicator ions critical for 
discrimination. For example, the ratios of fragments b3 to b2 of NWFa and NdWFa (referred to 
as RD and RL, respectively) were used as chirality reporters to distinguish the D- versus L-form 
and determine the fraction of the D-peptide. 
Interestingly, the fragment ions that showed the most pronounced changes in relative 
abundance between the D- and L-forms were not always the flanking residues of the D-amino 
acid, as also observed by others.12, 46 For the peptides we examined, the a4, b4, z4 and y2 ions 
varied the most between YAEFLa and YdAEFLa (Figure 3.3C), as can be visualized with the 
representative spectra in Figure 3.5; and y2 and MH-H2O showed the most significant changes 
between the two epimers for GFFD and GdFFD (Figure 3.3D). This suggests that the substitution 
of a single D-amino acid has an impact on the overall conformation of the peptide, rather than 
only on the neighboring residues, resulting in complex changes in fragmentation patterns.  
Using direct fragmentation we successfully discriminated all five pairs of peptide epimers 
but found that the chirality-reporting product ion abundances for GFAD and GdFAD, and FMRFa 
and FdMRFa, were fairly similar. Therefore, to maximize the sensitivity of these assays we 
explored the fragmentation differences in metal-complexed cations of these epimers. The sodium 
adducts present in the peptide standards have shown promise for enhancing chiral discrimination 
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when protonated peptides only show minimal differences.54 As seen in Figure 3.6, the Na+-
cationized peptides generated a different set of fragment ions from the protonated peptides and 
several pairs of product ions were used for chiral discrimination, some of which led to an 
enhanced chiral recognition factor (Rchiral=RD/RL). This effect may be due to different binding 
sites or the orientation of sodium ions on the peptide.54 The variation between runs is significant 
when compared to the fragmentation of protonated peptides, partly due to the low intensities of 
the product ions. It may be that this is a result of a low abundance of salt adducts, or a lower 
fragmentation efficiency of these adducts due to the charge stabilization effect.  
Another option is to use added metal species to enhance the discrimination power. As 
adapted from the kinetic method,43, 55 transition metal ions can be added to the sample for metal-
peptide complex formation. Here, cobalt chloride was used to discriminate FMRFa and FdMRFa. 
These two peptides are difficult to discriminate when assayed directly, but showed obvious 
differences with cobalt adduct fragmentation (Figure 3.4). 
When one assays a tissue sample, partially processed and final peptide products will be 
present. Thus, it is expected that the peptide will be present in both the L- and D-forms, and so 
measuring the relative abundance of each helps us to understand the importance of DAACPs as 
signaling molecules. Among the four pairs of peptides, protonated NWFa and NdWFa had the 
most distinct fragmentation profiles, with the b2 and b3 ions demonstrating a large Rchiral of 3.18, 
making this pair a good model to be used for isomeric content measurement.  
According to the following calculations, the RM measured from two chiral indicator ions 
of the mixture is correlated with the mole fraction of the D-epimer.45 For an L- and D-form 
mixture of a peptide, α being the mole fraction of the D-form:45, 56  
∆(∆G)M = α*∆(∆G)D + (1-α) *∆(∆G)L  (Eq. 1): 
with this leading to:  
ln RM = ∆(∆G)M / RT = ∆(∆G)L / RT + [(∆(∆G)D -∆(∆G)L) / RT) * α = ln ( RL ) + ln ( Rchiral ) * α. 
(Eq. 2) 
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Therefore, ln RM is linearly proportional to α. In this equation, ∆G is the free energy change in the 
fragmentation process, ∆ (∆G) is the difference of ∆G between two fragmentation pathways, R is 
the branching ratio of two fragmentation pathways, which approximately equals the abundance 
ratio of the two fragment ions, RM represents the measured abundance ratio of these two chirality-
reporting ions obtained from the isomeric mixture, and Rchiral equals the ratio of RL and RD.  
Based on Equation 2, a calibration curve (Figure 3.7) was created using a mixture of the 
D- and L-peptide standards, thus allowing the isomeric content to be calculated (ln RM=0.1495 
+1.1181*α, with the squared correlation coefficient R2 = 0.9757); standards were co-spotted with 
an endogenous peptide mixture extracted from the buccal ganglion of A. californica that did not 
contain the target analytes. Adding the endogenous peptide mixtures without target analytes 
allows the complexity expected in later biological samples to be mimicked without perturbing the 
measured isomeric ratio. The high data consistency and linearity shown in this curve 
demonstrates that the approach can be used for accurate isomeric determinations. The deviations 
from linearity may result from an unequal affinity of the two epimers to salt adducts.  
We applied this method to determine the conformation of NdWFa/NWFa in a direct assay 
from individually isolated neurons. Although Morishita et al.7 reported the NWFa peptide in the 
R3-R13 neurons, we did not detect it in those cells; instead, a mass corresponding to NWFa was 
detected in a small cluster of whitish, medium-sized neurons located on the lateral edge of the 
upper right rostral quadrant of the abdominal ganglion, as well as in several white neurons at the 
medial edge of the quadrant (the mass fingerprint of these cells is shown in Figure 3.1). Because 
the target peptides are of relative low-abundance, the cell salt rinsing step was critical to reducing 
interference of salts from the ASW and enhanced MS detection. DHB was found to be more 
suitable for these measurements because of its higher salt tolerance (as found in neurons) 
compared with α-cyano-4-hydroxycinnamic acid, and the improved peak resolution relative to 
concentrated DHB matrices. MS/MS analysis was performed using these peptidergic neurons 
(Figure 3.2). 
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Ten animals were used for the isomeric content measurements. The average percentage of 
NdWFa measured is 89.5 ± 9.6%, indicating that the content of the DAACP epimer is 
surprisingly high in these relevant neurons. This is in agreement with previous capillary 
electrophoresis measurements49 and may indicate that the equilibrium is toward converting most 
of the peptide into the D-amino acid-containing form. Furthermore, this supports the observation 
that it takes three orders of magnitude higher concentration of NWFa than NdWFa to induce the 
same heart beating amplitude;7 the high percentage also may support the idea that the D-form is 
more resistant to endogenous enzymatic digestion than the L-form. Lastly, when observing 
peptide contents from cells, one observes both the final products and processing intermediates, 
and so the small amount of the L-form peptide may indicate that the conversion occurs on a faster 
time scale than the release of these peptides. Regardless, our data demonstrates that most of the 
NWFa exists as the NdWFa peptide.   
Overall, this study shows that DAACPs with the 2nd-residue substitution were 
distinguished from their all-L variants using direct MS/MS methods; the isomeric content of a 
DAACP was quantified within a complex mixture in samples as small as several neurons. With 
the use of synthetic standards, chirality-reporting fragment ions are identifiable by comparing the 
abundance of respective major fragments from the epimers having the 2nd-position isomerization 
using MALDI MS. The chiral recognition factor varies with specific peptide sequences, but most 
of the biologically relevant peptides tested are discriminated, sometimes with the use of metal-
complexed cations. In biological samples, the ratio RM calculated from these reporters can be 
used to determine the natural isomeric content based on calibration curves obtained with 
standards. If prior knowledge about the target peptide is available, single cells or tissue samples 
can be assayed and the fraction in each form characterized. This option provides an advantage 
because the direct cell measurements involve samples where the target peptide is more 
concentrated and the ratios provide information on peptide forms within a biological context. 
Although no general features associated with DAACPs have been determined that allow 
their “blind” identification, this study demonstrates a fast and sensitive downstream approach to 
 67 
 
confirm candidates that potentially contain a D-amino acid. Using MALDI MS rather than other 
ionization techniques allows multiple experiments to be conducted within the same sample spots, 
so that peptides can be surveyed in a high-throughput fashion and then selected samples can be 
tested using the chiral measurements. This method, together with high-throughput enzymatic 
screening of complex peptide samples,42 provides an important addition to the approaches needed 
to characterize novel DAACPs.   
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FIGURES AND TABLES 
 
 
 
Figure 3.1. Two representative mass spectra demonstrating the peptide profile of the isolated 
neurons from A. californica. These neurons contain several peptides from the MIP-related peptide 
precursor and R3-14 peptide precursor. Reproduced with permission from Bai et al. (Copyright 
2010 American Chemical Society).1 
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Figure 3.2. MS/MS profiles of endogenous N(l/d)WFa compared with synthetic NWFa and 
NdWFa standards. (A). Two typical MS/MS mass spectrums generated from m/z 465.2, acquired 
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from relevant neurons isolated from the abdominal ganglia of A. californica. (B). Fragmentation 
patterns of the NdWFa and NWFa standards. Reproduced with permission from Bai et al. 
(Copyright 2010 American Chemical Society).1 
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Figure 3.3. Comparison of fragmentation patterns between D- and L-epimers measured by 
normalized peak intensity. Four pairs of synthetic epimers are shown here: (A). N(d/l)WFa; (B). 
G(d/l)FAD; (C). Y(d/l)AEFLa; (D). G(d/l)FFD. The chiral recognition factor is greatest for the 
fragment ions with the greatest relative differences (as listed in Table 3.1). Error bars represent 
the standard deviation calculated from six replicates (n = 6). Reproduced with permission from 
Bai et al. (Copyright 2010 American Chemical Society).1 
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Figure 3.4. Enhanced chiral recognition of F(d/l)MRFa using cobalt(II)-cationized peptides; here 
the pair of [b3-H+Co]+ and 612.02 ions provides the greatest discrimination (bottom panel), with 
Rchiral = 2.88 compared to Rchiral = 1.16 for the pair of b3 and y3 in the original fragmentation 
profile (top panel) ; n = 6. Reproduced with permission from Bai et al. (Copyright 2010 American 
Chemical Society).1 
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Figure 3.5. Representative spectra of the bar graphs shown in Figure 3.3C showing typical 
fragmentation patterns of YAEFLa and YdAEFLa. The relative abundance of b4 compared to 
other major product ions is low, with y2 and b4 ion pair forms an obvious contrast between the 
two epimers. Reproduced with permission from Bai et al. (Copyright 2010 American Chemical 
Society).1 
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Figure 3.6. Chiral discrimination of G(d/l)FAD using sodium adducts (bottom panel) is enhanced 
more than three-fold compared to protonated peptides (top panel), and as summarized in Table 1, 
by using the product ion pairs [y2-H2O]+ and [C3+Na]+ instead of b3 and y2 ions; n = 6. 
Reproduced with permission from Bai et al. (Copyright 2010 American Chemical Society).1 
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Figure 3.7. Calibration curve plotted with ln(intensity of b3/intensity of b2) against increasing 
content of D-isomers in the two-peptide mixture co-deposited with peptides extracted from the 
buccal ganglia. Technical replicates from six different spots were made for each RM value. 
Reproduced with permission from Bai et al. (Copyright 2010 American Chemical Society).1 
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Table 3.1. The five pairs of synthetic peptides, their chirality-reporting fragment ions and the 
corresponding chiral recognition factors.  
(M+H) + 
m/z 
(mono) 
Peptide Sequence 
Chirality-
reporting 
fragments 
Ratio of chirality-
reporting 
fragments  
(measured by 
peak intensity) 
 
Rchiral=
RD/RL 
465.2 N(l/d)WFa 
Asn-Trp-Phe-NH2 
b3 and b2 
1.28 ± 0.03 
2.97  
Asn-DTrp-Phe-NH2 3.78 ± 0.06 
641.3 Y(l/d)AEFLa 
Tyr-Ala-Glu-Phe-Leu-NH2 
b4 and y2 
0.043 ± 0.002 
2.51  
Tyr-DAla-Glu-Phe-Leu-NH2 0.111 ± 0.002 
485.2 G(l/d)FFD 
Gly-Phe-Phe-Asp Y2 and 
MH+H2O 
0.13 ± 0.02 
1.78  
Gly- DPhe-Phe-Asp 0.23 ± 0.02 
599.3 F(l/d)MRFa 
Phe-Met-Arg-Phe-NH2 b3 (or y3-NH3) 
and y3 (or c3) 
7.65 ± 0.18 
1.14  
Phe-DMet-Arg-Phe-NH2 8.7 ± 0.2 
657.3 
F(d/l)MRFa 
Cobalt 
adduct 
[M-H++Co]+ 
b3+Co and 
615 
0.30 ± 0.1 
2.80  
0.73 ± 0.09 
b3+Co and 
612 
0.10 ± 0.03 
2.88  
0.33 ± 0.05 
b3+Co and 
a3+Co 
0.26 ± 0.01 
1.62  
0.40 ± 0.03 
b3+Co and c3 
(or y3) 
0.101 ± 0.008 
1.60  
0.16 ± 0.02 
409.2 G(l/d)FAD 
Gly-Phe-Ala-Asp 
b3 and y2  
1.00 ± 0.02 
1.20  
Gly- DPhe-Ala-Asp 1.21 ± 0.01 
431.2 
G(d/l)FAD 
Sodium 
adduct 
[M+Na]+ 
c3+Na and y2-
H2O 
7.6 ± 5.3 
3.44  
26 ± 12 
c3+Na and 
a3+Na  
2.02 ± 0.08 
1.29  
2.6 ± 0.1 
c3+Na and 
b3+Na  
1.9 ± 0.2 
1.28  
2.4 ± 0.3 
 
Single letter codes are used for the amino acids, with a terminal “a” indicating an amidated C-
terminus, and a small “l” or “d” denoting that the following residue is in the L- or the D-form.) 
Rchiral is distinct for each pairs of chirality reporters, RL and RD calculated by dividing the peak 
area of the former by the latter chirality reporters in the table. Enhanced discrimination power of 
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this method on F(l/d)MRFa and G(l/d)FAD are realized via metal-complexed cations (cobalt 
adducts and sodium adducts respectively) instead of protonated peptides as precursors for 
fragmentation. A different set of product ions are found with metal adducts, which have different 
Rchiral. With such adducts, a higher discrimination power is measured but with higher standard 
deviation. Reproduced with permission from Bai et al. (Copyright 2010 American Chemical 
Society).1 
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CHAPTER 4  
 
CHARACTERIZATION OF G(D)FFD, A D-AMINO 
ACID-CONTAINING NEUROPEPTIDE IN THE 
CENTRAL NERVOUS SYSTEM OF APLYSIA  
 
Notes and Acknowledgements 
This chapter describes the characterization of a D-amino acid-containing neuropeptide, 
Gly-DPhe-Phe-Asp (GdFFD), and an all-L form homologous peptide of the know DAACP, Tyr-
DAla-Glu-Phe-Leu-amide, from Aplysia californica. Dr. Elena V. Romanova performed single 
cell isolation to obtain GFFD/GdFFD-containing neurons and provided valuable advice on single-
cell MALDI experiments. Itamar Livnat performed microbore HPLC separation and provided 
fractions containing GFFD/GdFFD from cerebral ganglia. Xiying Wang assisted with animal 
dissection. Dr. Ferdinand Sven Vilim from Professor Klaude Weiss’s performd the original 
molecular work to find the prohormone gene, and then performed (and shared) 
immunohistochemical staining and in situ hybridization results to help locate GFFD/GdFFD-
containing neurons in the pedal ganglia. Dr. Jian Jing performed electrophysiological experiments 
to assess the bioactivity of GFFD and GdFFD. Dr. Peter M. Yau and Dr. Brian S. Imai from the 
Biotechnology Center synthesized peptide standards. This work is supported by NSF CHE-11705 
and NIH through R01 NS31609 (to JVS).  
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4.1 ABSTRACT 
In this chapter, we characterized a novel D-amino acid-containing neuropeptide Gly-D-Phe-Phe-
Asp (GdFFD) from Aplysia californica. GdFFD is detected by liquid chromatography-mass 
spectrometry (LC-MS) in both pedal and cerebral ganglia. GdFFD demonstrates high efficacy in 
inducing egestive feeding programs in the cerebral ganglia. GdFFD is a homolog of a D-amino 
acid-containing neuropeptide GdFAD discovered from the African giant land snail Achatina 
fulica.  
 We also identified, in Aplysia, the all-L form homologous peptide of YdAEFLa, a 
DAACP originally discovered from Achatina fulica. These two discoveries, taken together, 
indicate that isomerization of peptides is not parallel between two related species.     
 
4.2 INTRODUCTION 
Neuropeptides are essential players in the central nervous system (CNS). They are involved in 
almost all aspects of animal physiology.1-4 Although like most other animal peptides, 
neuropeptides are considered to contain exclusively of L-amino acids, recent discoveries indicate 
otherwise. Without proper assay methods, it has been difficult to assay how prevalent D-amino 
acids are in neuropeptides, and many of them may have been neglected in sequencing 
experiments and peptidome research.  
Among the 30 D-amino acid-containing peptide (DAACP) known, Achatin-I is the first in 
the neuropeptide category.5 It was shown to induce voltage-dependent inward sodium current, on 
the periodically oscillating neuron (PON), in a strictly stereospecific fashion. Possible 
physiological functions include inducing greater amplitude and frequency of heart beat and 
excitatory effects on several other muscles.6 Later, a homologous sequence, Gly-D-Phe-Gly-Asp 
named ocp-1 was isolated from the Japanese octopus, Octopus minor.7 Ocp-1 has shown similar 
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cardioexcitatory effects with Achatin-I, and was 3-4 orders of magnitude more effective than the 
L-Phe2 counterpart.  
Another gene that attracted interests for stereoisomer research in Achatina fulica was the 
nine fulicin gene-related peptides (FGRP-1 to -9). Fulicin (Phe-D-Asn-Glu-Phe-Val-NH2)8 and 
fulyal (Tyr- D-Ala-Glu-Phe-Leu-NH2)9 were both isolated from the same species. Both have 
shown 3-5 orders of magnitude higher activities than their all-L form conformation.  
Aplysia has homologs for both Achatin-like peptides and FGRP. Here we describe the 
discovery of a novel D-amino acid-containing peptide (DAACP) in Aplysia californica, Gly-D-
Phe-Phe-Asp, and an all-L form conformation of fulyal, Tyr- Ala-Glu-Phe-Leu-NH2. 
 
4.3 EXPERIMENTAL SECTION 
Materials. Chemicals and reagents: Water was purified from a Milli-Q system (Millipore, 
Bedford, MA,); the antibiotics, 2,5-dihydroxybenzoic acid (DHB), acetonitrile (ACN) containing 
0.01% trifluoroacetic acid (TFA), were obtained from Sigma-Aldrich (St. Louis, MO). Peptide 
standards: YAEFLa, GFFD, and the corresponding epimers with D-amino acids in the second 
position, were synthesized by the Protein Sciences Facility, University of Illinois (Urbana, IL).   
 
Animals. Aplysia californica (120–170 g) were purchased from the University of Miami/NIH 
National Resource for Aplysia and kept in an aquarium containing aerated and filtered artificial 
seawater (Instant Ocean, Aquarium Systems Inc., Mentor, OH) at around 14 °C until used. Prior 
to dissection, animals were anesthetized by injection of isotonic MgCl2 (30 to 50% of body 
weight) into the body cavity.  
 
Neuron Isolation. The abdominal ganglia were dissected and incubated in artificial sea water 
(ASW: 460 mM NaCl, 10 mM KCl, 10 mM CaCl2, 22 mM MgCl2, 6 mM MgSO4, and 10 mM 
HEPES, pH 7.8) supplemented with antibiotics (penicillin G, gentamycin and streptomycin) and 
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containing 1% (w/v) protease (Type IX: Bacterial; Sigma-Aldrich) at 32 °C for 45 min to loosen 
the connective tissue sheath. Following a 1–3 h rinse in ASW with antibiotics to remove the bulk 
of the protease, the ganglia were stretched onto a silicone elastomer (Sylgard, Dow Corning, 
Midland, MI) layer in a petri dish containing 3–4 mL of the ASW-antibiotic medium using 0.15 
mm diameter tungsten needles (WPI, Sarasota, FL) and connective tissue was surgically removed 
to expose neurons.  
Clusters of peptidergic neurons from individual A. californica containing G(l/d)FFD were 
identified according to their position, size, and pigmentation. For MALDI-TOF/TOF analysis, 
isolated neuron clusters were briefly rinsed in Milli-Q water to remove excess salts and ASW 
before depositing onto the MALDI target. Excess liquid was aspirated from the target and spot-to-
spot cell transfers were performed for sampling of individual neurons as described previously. 
Between 0.2–0.4 µL of 10 mg/mL DHB matrix was applied by the dried droplet method over the 
lysed cells.  
 
MALDI TOF/TOF MS Analysis. These analysis adopts previously reported protocols.10 MS 
measurements were performed using an UltrafleXtreme MALDI time-of-flight (TOF)/TOF mass 
spectrometer (Bruker Daltonics, Billerica, MA) in positive-ion reflector mode. MS/MS 
measurements were performed in “LIFT” mode with CID turned on. Collision was performed 
with argon gas, creating a source pressure of 6 × 10-6 mbar, and the collisional energy was 
typically set to 27 keV, including a potential raise in the “LIFT” chamber. External peptide 
standards were used for calibration of the MS and MS/MS in the low mass range.  
For the synthetic peptides, 0.7 μL of 1 mg/mL of each was dissolved in water, deposited 
on the target, and mixed 1:1 (v/v) with matrix: 10 mg/mL of DHB in 50% ACN with 0.01% TFA. 
For each sample, three replicate spots were characterized. For each replicate, the spectrum was an 
average of 5,000 laser pulses. The same instrument settings were used for the synthetic peptide 
samples that included mixtures of the D- and L-standards.  For the single-cell measurements, 
conditions were the same, except that laser intensity was adjusted to observe peaks with a signal-
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to-noise ratio higher than 100 but not saturated; this value was kept consistent across the cell 
samples from each animal.  
The MS/MS spectra were analyzed using the FlexAnalysis and Biotools software 
packages (Bruker Daltonics). Statistics was performed with intensity/area values exported from 
FlexAnalysis. Statistical calculations, including mean and standard deviation for bar charts and 
calibration curves, were performed using Microsoft Excel 2010. To compare fragmentation 
patterns between two epimers, intensity values for each fragment ion were normalized to the sum 
of all major fragment ions produced from the particular sample spot (except for results from 
metal adducts, which were normalized to the most intense peak as the metal adduct example 
contained large numbers of low intensity peaks).  The observed fragment ion peaks were mass 
matched to predicted fragment ions using Protein Prospector 
(http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msproduct).   
 
Preparation of neuropeptide extracts from biological tissues. Extracts are prepared with 
acidified acetone (40:6:1 acetone: H2O: HCl, v/v/v), sonicated briefly and centrifuged 
(Centrifuge 5804R, Eppendorf, Westbury, NY, USA). The supernatant was collected. An equal 
volume of fresh acidified acetone was added to the insoluble, vortexed to resuspend, and stored in 
4 centigrade overnight. After centrifugation, supernatant was collected and combined with the 
portion prepared previously, and the insoluble was discarded. The combined supernatant was then 
dried in a vacuum evaporator SpeedVac (Savant Instruments, Farmingdale, NY), and 
reconstituted in 5% ACN in water (95% H2O/5% CH3CN/ 0.01% TFA (v/v/v)).  
 
First-stage Microbore HPLC fractionation. For extracts prepared from the cerebral or pedal 
ganglia, reconstituted samples were fractionated with a microbore HPLC system (Magic 2002, 
Michrom Bioresources, Auburn, CA, USA) with a reversed-phase C18 column (150 × 1.0 mm 
i.d., 5 μm particle size, 300 Å pores, Dionex, Sunnyvale, CA) at a flow rate of 20 μL/min prior to 
LC-MS analysis.  
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A UV/Visible detector set at 220nm was used for detection. A binary solvent system was 
used with solvents A (95% H2O/5% ACN/0.1% formic acid/0.01% TFA (v/v/v/v)) and B (95% 
ACN/5% H2O/0.1% formic acid/0.01% TFA (v/v/v/v)). The solvent gradient started by increasing 
B from 1 to 5% over 5 min, up to 50% over the next 45 min, and followed by a 20 min gradient 
from 50% to 80% B. Fractions were manually collected using a fraction collector (FC 203B, 
Gilson, Middletown, WI). 
 
LC-MS analysis of peptide epimers and biological samples. Synthetic peptide epimers GFFD 
and GdFFD were prepared in three solutions, 1µg/ml GFFD, 1µg/ml GdFFD, and a mix of both. 
Separation was performed on a C18 column with RP-HPLC coupled to ESI-Ion Trap MS. 
Each microbore HPLC fraction of interest was analyzed using a capillary LC-Electrospray 
Ionization (ESI)-Ion Trap (IT) MS (CapLC-ESI-IT MS) setup. The capillary HPLC system 
(CapLC, Waters Corporation, Milford, MA) was equipped with a Dionex C18 PepMap column 
(150×0.3 mm i.d., 3 μm particle size, 100 Å pore size) running at a flow rate of 2.5 μL/min. 
Gradient elution was adopted (A: 0.05% TFA (v/v); B: 80% ACN, 20% H2O and 0.04% TFA). 
The eluent was interfaced online with an electrospray ionization (ESI) ion trap (IT) mass 
spectrometer (HCTultra PTM Discovery System, Bruker Daltonics, Ballerica, MA, USA).  
A binary solvent system with different physicochemical properties from the first dimension 
microbore LC (A: 95% H2O, 5% MeOH, 0.1% formic acid and 0.01% TFA (v/v); B: 95% MeOH, 
5% H2O, 0.1% formic acid and 0.01% TFA (v/v)) was used, in order to get different selectivity 
and partition to better separate the peaks. The MS interfaced downstream of the capLC was an 
ESI-IT mass spectrometry (HCTultra PTM Discovery System, Bruker Daltonics, Billerica, MA). 
Data was acquired under positive-ion mode with detection ranges of m/z 300-1500 and 50-2000 
for MS and MS/MS respectively.  
Collision-induced dissociation (CID) was the choice for MS/MS analysis. The software 
parameters for data acquisition were set so that during each MS scan, two most intense precursor 
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ions were selected for MS/MS analysis, and dynamic exclusion is in effect to exclude precursor 
ions which have been subjected for fragmentation twice within one minute. Ions carrying two 
charges were set to be preferred precursors. 
A hypercarb column (100×0.32 mm i.d., 5 μm particle size, Thermo Scientific, Waltham, 
MA) was used for optimized separation of YAEFLa and YdAEFLa. The same gradient and 
solvent system as that for capLC on a C18 column was used. 
 
In-situ hybridization. In-situ hybridization was performed as described previously. 11 Ganglia 
were digested with 1% protease type IX (Sigma-Aldrich, St. Louis, MO) in 10 ml of artificial sea 
water (ASW: 460 mM NaCl, 10 mM KCl, 55 mM MgCl2, 11 mM CaCl2, and 10 mM HEPES, pH 
7.6) for 3 h at room temperature (with rocking) to facilitate the removal of the sheath.  After 
digestion, the ganglia were washed with ASW and fixed overnight at 4°C with 4% 
paraformaldehyde (Electron Microscopy Sciences, Fort Washington, PA) in phosphate-buffered 
saline (PBS).  The ganglia were then washed, desheathed, dehydrated in an ascending ethanol 
series, and then rehydrated.  Following rehydration, the ganglia were prehybridized and then 
hybridized overnight at 50°C in HYB buffer (50% formamide, 5 mM EDTA, 5 SSC, 1 
Dernhardt’s solution, 0.1% Tween 20, and 0.5 mg/ml yeast tRNA) containing 2 μg/ml 
digoxigenin-labeled cRNA probes made from the corresponding cDNA templates.  Following 
wash-out of the probes, the ganglia were then incubated overnight at 4°C with a 1:200 dilution of 
alkaline phosphatase-conjugated anti-digoxigenin antibody (Roche Molecular Biochemicals, 
Indianapolis, IN) in PBS containing 0.1% tween, 0.2% bovine serum albumin (BSA) and 1% 
normal goal serum (NGS).  After washes with PBT to remove unbound antibody, the ganglia were 
washed with detection buffer (100 mM NaCl, 50 mM MgCl2, 0.1% tween 20, 1 mM levamisol, 
and 100 mM Tris-HCl, pH 9.5) and developed with 4.5 μl of nitroblue tetrazolium and 3.5 μl of 
5-bromo-4-chloro-3-indolyl phosphate (Roche Molecular Biochemicals, Indianapolis, IN) in 1 ml 
of detection buffer.  The staining reaction was monitored visually and stopped by washing with 
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PBT when the level of staining was adequate.  The stained ganglia were photographed using a 
Nikon microscope (Morrell Instruments, Melville, NY) with epi-illumination against a white 
background.  Photographs were taken with a Nikon CoolPix 990 digital camera, imported into 
Photoshop, and compiled into figures. 
 
Analysis of electrophysiological activity in the feeding circuit. Intracellular and extracellular 
recordings of physiological activity from CNS preparations (the cerebral) were performed as 
described previously.12 Synthetic GFFD and GdFFD (purified to 99.9%--100%) were perfused 
onto the tissue preparation respectively and electrophysiological responses with or without 
perfusion of peptides were recorded. The ganglia were desheathed, and transferred to a recording 
chamber containing ~1.5 ml of ASW, continuously perfused at 0.3 ml/min, and maintained at 14–
17 °C. Peptides were dissolved in ASW immediately before each application and the ASW with 
the peptide was perfused into the recording chamber.  Intracellular recordings were obtained 
using 5-10 MΩ sharp microelectrodes filled with 2 M K acetate and 0.3 M KCl. 
Electrophysiological recordings were digitized online with Axoscope (Molecular Devices, Inc., 
Sunnyvale, CA) and plotted with CorelDraw (Corel Inc., Mountain View, CA).  
 
4.4 RESULTS 
Homologs of DAACPs in Aplysia californica. Mollusks have been a rich source for neuropeptide 
discoveries. Several D-amino acid-containing neuropeptides have been discovered from the 
African giant land snail Achatina fulica, including Achatin-I (GdFAD),5 fulicin (FdNEFVa),13 and 
fulyal (YdAEFLa), 9 with the latter two produced from the same prohormone.  
Achatin-I was previously found from the suboesophageal and cerebral ganglia in Achatina 
fulica, and an excitatory effect through induction of inward sodium current was observed in 
periodically oscillating neuron (PON)5, which was specific for this particular diastereomer rather 
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than any other possible epimers. Later, isolation of fulicin and fulyal from the same species was 
reported and these peptides were shown to be 100- and 10,000-fold more potent in potentiation of 
the tetanic contraction of the snail penis retractor muscle than their all-L form counterparts 
respectively.9, 13  
The presence of a 158 amino acid-long prohormone in Aplysia californica, homologous to 
the Achatin precursor, is indicated by cloning of its cDNA by Klaude Weiss and Sven Vilim at our 
request when we became interested in DAACPs, and then later deposited in the UniProt database 
(http://www.uniprot.org/uniprot/Q5MAR6) under the name Achatin-like neuropeptide. Sequence 
alignment between Achatin precursor (UniProt id Q9Y096) and Achatin-like neuropeptide 
(UniProt id Q5MAR6) shows seven repeats of G(l/d)FAD, and at those loci there are several 
homologous sequences in Aplysia californica, including GYFD (m/z 501.2), GFFD (m/z 485.2, 
with three repeats), GDAS (m/z 349.1), SYAD (m/z 455.2), and GFFG (m/z 427.2).  
 Similarly, Fulicin Gene-Related Peptide prohormone, analogous to the Fulicin precursor, 
has also been cloned previously from Aplysia californica by Weiss and Vilim. Peptides were 
predicted from this 352 amino acid-long prohormone using a bioinformatics tool, NeuroPred 
NeuroPred (http://neuroproteomics.scs.illinois.edu/cgi-bin/neuropred.py), a web-based tool 
developed in the UIUC Center for Neuroproteomics on Cell-Cell Signaling to predict cleavage 
from the different logistic regression and the Known Motif models.14 Predicted neuropeptides 
include LSRMLLNGQLAEQYPEFIa (m/z 2121.1), RPYDFLa (m/z 809.4), NPYEFIa (m/z 
781.4), NPYEFVa  (m/z 767.4), QWEFVa (m/z 707.3), FTEFLa (m/z 655.3), SYDFLa (m/z 
643.3), YAEFLa (m/z 641.3), PYDFVa (m/z 639.3), YDFLa (m/z 556.3), and YDFVa (m/z 
542.2).  
 
Identification of GFFD and GdFFD using LC-MS.  In order to determine if these prohormones 
are expressed and what peptides they encode, we performed analytical separations on appropriate 
ganglion extracts. First, synthetic GFFD and GdFFD were separated on a C18 column with 
reversed-phase HPLC coupled to ESI-Ion trap-MS. The retention time was 21.4 min and 24.3 min 
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respectively (Figure 4.3). The elution order was determined by running each epimer separately. 
Tandem MS with CID generated similar fragment ions for two epimers, although the relative 
intensities of each are different.  
Neurons expected to contain these peptides were identified based on in situ hybridization 
staining (Figure 4.1) of cDNA corresponding to GFFD/GdFFD. The cluster of neurons is 
identified at the base of one of the large nerves on the dorsal side of the pedal ganglia. Extracts 
were prepared from the isolated neurons, and reconstituted solution was then used for LC-MS 
analysis. Peptide profiles were obtained using MALDI MS and are shown in Figure 4.2. Several 
peptides from the Achatin-like neuropeptide precursor were detected from these neurons, 
including m/z 484.9 matching that of GFFD/GdFFD.  
To determine whether the peak detected from MALDI MS is in the L- or the D-form or a mix 
of both, separation is needed. LC-MS methods were optimized using synthetic counterparts of 
GFFD and GdFFD, and both were separated using RP-HPLC on a C18 column (Figure 4.3). 
Tandem MS fragmentation profiles were also generated from CID and can be referenced against 
the biological samples. LC-MS chromatogram in Figure 4.4 shows identification of both GFFD 
and GdFFD from the neurons isolated from the pedal ganglia. Both retention time and tandem 
MS fragment ions match those of synthetic standards. As described in our previous work, using 
distinctive tandem MS fragmentation patterns from MALDI-TOF/TOF analysis, peptide epimers 
can be discriminated from each other.10 Here, a limited number of spectra were obtained from 
each epimer, but the difference in fragmentation patterns shown in Figure 4.4 is typical.  
 Extracts were also prepared from the cerebral ganglia and were fractionated using a 
microbore HPLC to simplify the peptide contents prior to LC-MS analysis. The LC-MS 
chromatogram and fragmentation spectra also confirmed the presence of GdFFD in the cerebral 
ganglia.   
 
MALDI-TOF/TOF fragmentation analysis of isolated neurons from the pedal ganglia. Besides 
LC-MS analysis, neurons isolated from the pedal ganglia were also subjected to MALDI-
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TOF/TOF analysis to confirm the chirality determination.  
 Figure 4.5 shows the differential fragmentation patterns between synthetic GFFD and 
GdFFD. Fragmentation patterns were measured by the ratio of two discriminative fragment ions 
(for example, y2 and b3 ions) and they are associated with the particular chiral form. 10 All-L and 
the D-amino acid-containing forms were discriminated based on different ratios with very small 
variation among three samples. Both peak intensity and peak area were used for these 
measurements and two sets of data agreed with each other. The ratio from the neurons was 
between GFFD and GdFFD and biased toward GdFFD, indicating the neurons contain a mix of 
both GFFD and GdFFD, with the D-form being more abundant. This result confirms the analysis 
using LC-MS. 
   
Bioactivity tests with GFFD and GdFFD. Tests for physiological effects were performed on a 
cerebral ganglia preparation in feeding network neurons. GdFFD was able to induce largely 
egestive programs at very low concentrations (10-5 in one preparation as shown in Figure 4.7, and 
10-6 M in the other preparation). It also shortens protraction duration of CBI-2-elicited programs 
(data not shown). The motor programs induced were mostly egestive because B8 activity 
overlapped with the protraction phase (represented by B65 bursting). Consistently, B40, a neuron 
important for ingestive programs, although received cyclic inputs, was not active. In contrast, 
GFFD has little effect. Although it may shorten slightly protraction duration of CBI-2-elicited 
programs, it wasn’t able to induce programs. 
Other neuropeptides that were previously characterized by us includes Aplysia neuropeptide 
Y (apNPY) which promotes the egestive programs and reconfigures the feeding network by 
switching the cerebral-buccal interneuron-2, a command-like interneuron from commonly 
observed ingestive responses to egestive responses.12 Feeding Circuit-Activating Peptides 
(FCAPs), a family of eight different peptides from the same precursor, were shown to initiate 
feeding motor programs.15 The results reported here are valuable additions to our understanding 
of the feeding behaviors of Aplysia. And more importantly, the drastic efficacy difference 
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between GdFFD and GFFD in inducing these effects leads to the conclusion that the L-to-D 
conversion at Phe in GFFD was essential for proper physiological functions.  
 
Identification of YAEFLa from the cerebral ganglia. The FGRP peptides are rare in the CNS 
based on staining results. The neurons expressing them are found mainly in the cerebral ganglia 
and less often in the abdominal ganglia.   
 Two-stage HPLC separation was performed to identify YAEFLa/YdAEFLa. Each fraction 
generated from the first-stage was used for the second-stage LC-MS analysis. In order to 
comprehensively scan through the fractions in an efficient manner, fractions were combined in a 
way so that neighboring fractions from the first-stage were not combined in the same sample for 
second-stage analysis (e.g. fraction 1, 7, and 13 were combined).  
Synthetic YAEFLa and YdAEFLa were used to optimize separation and MS conditions. 
These epimers elute very closely on the C18 column, therefore, a hypercarb column was used. 
The difference of retention time increased from 0.8 min to 3.4 min which ensures more 
confidence in chirality determination by retention time (Figure 4.8). From all fractions obtained 
from the cerebral ganglia, only YAEFLa but not YdAEFLa was detected. Fragmentation profile 
that closely resembles the synthetic YAEFLa also supported this identification. Moreover, two 
other peptides from the same Fulicin Gene-Related Precursor have also been detected, further 
lending support to the correct identification of YAEFLa (Figure 4.9). 
This result shows that the isomerization of YAEFLa, unlike GFFD, is not conserved between 
Achatina fulica and Aplysia californica despite the identical sequence. This may shed more light 
on the substrate specificity of the hypothetical isomerase in Aplysia.  
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4.5 CONCLUSION AND DISCUSSION 
In this chapter, the discovery of a D-amino acid-containing neuropeptide, GdFFD, is described. 
Prior to this study, NdWFa was the only known DAACP in Aplysia.16 With two DAACPs 
discovered in Aplysia up to this point, we expect to find more of these because it is more obvious 
that NdWFa is not an exception. 
With electrophysiological studies, we have shown that proper activities require the 
isomerization of L-Phe to D-Phe. This neuropeptide, in the D-Phe2 form, is very robust in 
inducing egestive feeding motor programs in the cerebral ganglia. With its presence in the 
cerebral ganglia, it can be an important player in the feeding network. Being an enzyme-resistant 
peptide (Figure 4.6), GdFFD may have different time course of action and life cycle than other 
feeding network peptides. 
This study has strengthened the hypothesis that DAACPs are more common than we 
currently know, and the D-amino acid is critical for biological activities. With our ongoing studies 
of the Aplysia D-amino acid-containing peptidome, and peptidomics studies on several other 
model organisms, we expect to find more DAACPs. 
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FIGURES AND TABLES 
 
 
 
Figure 4.1. In situ hybridization staining of cDNA of GFFD/GdFFD. In all the pictures, the pedal 
commisure is facing downward (south) and the pleural ganglion is facing to either the left or 
right. The top two panels are the dorsal surfaces and the bottom two are the ventral surfaces. 
(from collaborator Dr. Ferdinand Sven Vilim)
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Figure 4.2. Peptide profile detected by MALDI-TOF MS from the cells stained positive for 
cDNA corresponding to GFFD/GdFFD in in situ hybridization. Several peptide products from 
Achatin-like peptide precursor are detected from these cells by accurate mass match.   
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Figure 4.3. The detection of synthetic peptides GFFD (retention time 21.4 min) and GdFFD (24.3 
min) using LC-MS. Their fragmentation patterns are shown in the lower panels.  
  
 101 
 
 
 
 
 
Figure 4.4. GFFD and GdFFD are detected from neurons isolated from the pedal ganglia from 
Aplysia californica using LC-MS. Fragmentation patterns of both match well with those of 
synthetic peptides, which confirms the identification. 
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Figure 4.5. GFFD and GdFFD can be distinguished by their different fragmentation patterns 
using MALDI-TOF/TOF MS. Each epimer has a unique ratio of two most discriminative 
fragment ions y2 and b3, and the ratio measured from isolated neurons is close to the value for 
GdFFD. 
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Figure 4.6. G(l/d)FFD-containing neurons isolated from the pedal ganglia in Aplysia californica 
are digested with Aminopeptidase M and the sodium adduct of G(l/d)FFD was detected as the one 
of the highest peaks, showing that G(l/d)FFD was resistant to enzymatic digestion. 
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Figure 4.7. GdFFD induces cyclic activity in the buccal central pattern generator (CPG). A, 
Control showing almost no activities for cells at rest without perfusion. B, During the perfusion 
of 10-5 M GdFFD, the feeding network became cyclically active. The motor programs induced 
were mostly egestive because B8 activity overlapped with the protraction phase (represented by 
B65 bursting). Consistently, B40, a neuron important for ingestive programs, although received 
cyclic inputs, was not active. C, After washout of the peptide, the preparation gradually returned 
to be inactive. Beginning of the trace: 4.2 min after the start of the washout. 
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Figure 4.8. YAEFLa, but not YdAEFLa, is detected using LC-MS. Green arrow points to the 
retention time for YAEFLa and gray arrow points to the retention time for YdAEFLa. MS/MS 
spectrum matches the expected fragmentation pattern of Y(l/d)AEFLa. The top panel shows 
separation with a hypercarb column, while the bottom shows the results from a C18 stationary 
phase. 
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Figure 4.9. Two other peptide products in addition to YAEFLa from the Fulicin Gene Related 
Peptide precursor (FGRP) are identified in the second-stage HPLC separation.   
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CHAPTER 5  
 
SCREENING METHODS FOR IDENTIFICATION 
OF D-AMINO ACID-CONTAINING PEPTIDES  
Notes and Acknowledgements  
This chapter describes two screening methods used to identify D-amino acid-containing 
peptides (DAACPs) candidates from crude biological tissue samples. One method uses enzymatic 
digestion approaches based upon the method created previously within the group by Michael A. 
Ewing, Jane Wang and Jonathan Sweedler.1 Important enhancements to the approach have been 
made and a workflow combining enzyme digestion and peptide characterization was established. 
A list of digestion-resistant peptides is generated from this enzyme-aided screening approach, 
which are flagged for follow-up studies. Aplysia peptidomics data (Sweedler group, unpublished) 
was used, some of which was from Dr. Fang Xie, Dr. Elena Romanova, Xiaowen Hou and former 
group members and collaborators; this data facilitated peptide characterization. Dr. Elena V. 
Romanova and Dr. Stanislav S. Rubakhin are acknowledged for advice on peptidase digestion 
conditions. The second method uses Ion Mobility Spectrometry (IMS) and was developed and 
validated using two different IMS system. One IMS system was employed in collaboration with 
the Waters Corporation. Dr. Peter Yau is acknowledged for making contacts with Waters demo lab 
and giving invaluable suggestions and guidance on this project. The other IMS experiments were 
conducted in collaboration with Professor David Clemmer’s group at Indiana University 
Bloomington. Michael A. Ewing, now working with Clemmer, performed many of the IMS 
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measurements with samples provided by us. Stephen J. Valentine and Rebecca Glaskin (also at 
Indiana University) are also involved in this project. This work is supported by NSF CHE-11705 
and NIH through R01 NS31609 (to JVS), the National Institute of Neurological Disease and 
Stroke under Award No. NS031069 and the National Institute of Drug Abuse under Award No. 
DA018310 to the UIUC Neuroproteomics Center on Cell-Cell Signaling. 
  
5.1 ABSTRACT 
In previous chapters, targeted analysis of DAACPs has been presented, which involves 
investigating a particular peptide of interest with reference information from corresponding 
synthetic peptides. Techniques including tandem mass spectrometry (MS) and high performance 
liquid chromatography (HPLC) were used to distinguish two synthetic epimers and their unique 
properties can be referenced against when analyzing the native peptide. Using these approaches, a 
DAACP has been discovered from Aplysia. 
This result lends further support to our hypothesis that DAACPs are more prevalent than 
we thought. While these approaches are robust and convenient, they do require the synthesis of 
standards, and cannot be used alone to identify DAACPs without having a target peptide. 
Identification of this isobaric modification in the presence of the complex neuropeptidome 
presents challenges in performing stereospecific analysis and characterizing the neuropeptide 
contents at the same time. Specifically, our initial samples are brain homogenates that contain 
literally hundreds of peptides with concentrations ranging over six orders of magnitude, we need 
to simplify the samples for further investigations. Therefore, we have tried different methods to 
generate a list of potential DAACP candidates to guide our follow-up studies; and the 
combination of these methods will minimize losses of potential DAACPs. 
The goal is to be able to take a complex mix and determine likely DAACP candidates so 
that greater efforts are used to characterize only those peptides. We expect the initial step to be 
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able to identify such a subset of peptides without the use of the LAACP and DAACP standards. 
Here, two screening methods to identify DAACPs found in complex mixtures without analyte 
preselection are described.  
One method is an enzyme digestion method with the use of Aminopeptidase M which 
preferentially digests LAACPs over DAACPs.1 Using this enzyme to digest a complex mixture of 
peptides results in a subset of peptides that are relatively difficult to degrade, and one possibility 
that may have contributed to the enzyme resistance is the presence of a D-amino acid near the N-
terminus of the peptide. Specific protocols have been developed to improve the specificity of the 
enzyme digestion approach to reduce the number of false negatives.  
 The other method exploits the capability of IMS to resolve molecules with identical 
molecular weight but subtle structural differences. Assuming both L- and D-forms coexist, this 
structural heterogeneity can be identified by the detection of two drift times corresponding to a 
single m/z.  
 A more direct way of identifying possible DAACPs is to find peptides that share the same 
m/z but can be resolved with liquid chromatography-mass spectrometry (LC-MS). This can either 
be done in a series of experiments or through searching previous peptidomics data from 
separation and sequencing experiments using LC-MS. This possibility will not be introduced here 
but will be described in more details in Chapter 7. 
 
5.2 INTRODUCTION 
The analysis of DAACPs in crude tissue samples requires conformational analysis in the presence 
of complex biological backgrounds, and so it is more than just separating two synthetic 
diastereomeric standards. It is common that hundreds to thousands of peptides are be present in a 
CNS extract, with a large dynamic range of concentrations.2-3 Low-abundant peptides are usually 
suppressed by more abundant ones during chemical characterizations. It is neither realistic nor 
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efficient to isolate each peptide and then synthesis the peptide to compare its retention and other 
properties with a synthetic all-L-form peptide to find the DAACP. Screening methods to find 
putative DAACPs become critical. While prior DAACP discovery was guided by bioactivity, here 
the goal is non-activity-based approaches.  
Since 1981 when Dermorphin was first isolated from the South American frog 
Phyllomedusa skin secretions,4 about 30 DAACPs have been described.5-6 Most discoveries were 
made because the peptide being isolated had a known bioactivity and there was a disparity in 
biological activities between the synthetic standards and the native peptide. Further analysis with 
a range of analytical methods was used to confirm these results. Putative DAACPs isolated from 
hundreds of animals are usually prepared for such chemical analysis. This discovery path is 
shared among most of the DAACPs known to date, but these experiments can take a long time, 
and are not used as often any more. Peptides discovery mode has now switched to a high-
throughput fashion, when hundreds of peptides are being sequenced at the same time. Commonly 
used sequencing techniques such as mass spectrometry and Edman degradation do not provide 
stereospecificity. The limited opportunities for DAACP identification partly explains why 
DAACPs were scattered in difference species. Even though the isolation of one DAACP suggests 
the presence of the isomerization machinery within the organism (and therefore more DAACPs 
are likely to be found), there haven’t been reports on systematic studies of DAACPs in one 
organism. The lack of systematic characterization is due to a lack of a robust method to address 
these challenges.   
 
5.3 MATERIAL AND METHODS 
Sample Preparation. Peptide standards: NWFa, NdWFa, YAEFLa, YdAEFLa, GdFAD, GFFD, 
GdFFD were synthesized by the Protein Sciences Facility, University of Illinois (Urbana, IL); 
Achatin-1 (GFAD), Angiotensin-I and α-BCP (APRLRFYS) were purchased from American 
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Peptide Company (Sunnyvale, CA). Chemicals and reagents: water was purified from a Milli-Q 
system (Millipore, Eschborn, Germany), 2,5-dihydroxybenzoic acid (DHB), acetone, 
concentrated HCl, and acetonitrile (ACN) containing 0.01% trifluoroacetic acid (TFA) were 
obtained from Sigma Aldrich (St. Louis, MO).  
Tissue extracts were prepared from desheathed Aplysia abdominal ganglia and 
homogenized in acidified acetone (40:6:1 acetone/water/concentrated HCl, v/v/v). Tissues were 
homogenized with a hand-held homogenizer in PCR tubes, centrifuged for 10 min at 14000 rpm. 
The supernatant was transferred to new vials and evaporated in a centrifuge vacuum drier 
SpeedVac (Savant Instruments Inc., Farmingdale, NY) until fully dried. The extract was then 
reconstituted with 5% ACN before use. 
CNS extracts were fractionated using a microbore HPLC (Magic 2002, Michrom 
Bioresources Inc., Auburn, CA) with a reverse-phase Dionex C18 column (150 × 1.0 mm i.d., 5 
μm particle size, 300 Å pores, Dionex, Sunnyvale, CA) at a flow rate of 20 μL/min. A UV/Visible 
detector set at 220nm was used for detection. A binary solvent system was used with solvents A 
(95% H2O/5% ACN/0.1% formic acid/0.01% TFA (v/v/v/v)) and B (95% ACN/5% H2O/0.1% 
formic acid/0.01% TFA (v/v/v/v)). The solvent gradient started by increasing B from 1 to 5% over 
5 min, up to 50% over the next 45 min, and followed by a 20 min gradient from 50% to 80% B. 
To equilibrate the column, the system was ramped to 5% B over 5 min and maintained at 5% B 
for 5 min. Fractions were manually collected using a fraction collector (FC 203B, Gilson, 
Middletown, WI).  
 
Enzyme Digestion. Aminopeptidase M (< 4 unit/mg, 3.3 mg/ml suspension in 3.2 M ammonium 
sulfate, 10 mM Tris, 10 mM MgCl2, pH 7.5) was purchase from Thermo Scientific (Pierce, 
Rockford, IL).  
A unit of APM hydrolyzes 1 mmol of L-leucine-4-nitroanilide per minute at 25°C, 
pH 7.2 (from Piercenet.com). Assuming 4 unit/mg of APM is suspended in 3.3 mg/ml 
buffer, 1 μL is able to release 0.0142 mmol amino acids per minute. A 50 μL system with 
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1 mM substrate contains 0.05 mmol peptides, and they can be consumed in a time scale 
of minutes if APM proceeds normally. Usually, 1 μL of enzyme solution, 10-20 μL synthetic 
peptide solutions (1 mg/mL) or biological samples, and 10-20 μL of Tris-HCl-NaCl buffer (25 
mM Tris-HCl-500 mM NaCl, pH 7.5) were mixed and incubated in 37Ԩ water bath.  
A software package, PAWS, (Genomic Solutions, Holliston, MA, 
http://bioinformatics.genomicsolutions.com/Paws.html) was used to identify fragments by 
matching query mass values with calculated masses that can be generated from a certain 
peptide. 
 
Mass Spectrometry Detection. To get complementary information to overcome the bias of 
different ionization methods, two different mass spectrometric methods were used. MALDI-TOF-
MS was used for quick mass analysis of digested samples; while LC-ESI-MS/MS was used for 
sequencing uncharacterized peptides.  
MALDI-TOF -MS  
MALDI-TOF MS (Ultraflex II; Bruker Daltonics, Billerica, MA) equipped with delayed 
ion extraction and a frequency tripled Nd:YAG laser operating at 1064 nm and 50 Hz was used 
for peptide characterization in proof-of-concept experiments with synthetic peptide standards. 
Detection was performed under positive-ion mode with reflectron mode on, and the range of 
detection was 420-5000 m/z. The instrument was calibrated externally using the Bruker peptide 
calibration standard II containing about 10 peptide standards spanning the detection range. The 
matrix used was 2,5-dihydroxybenzoic acid (DHB, 10 mg/mL in 50% ACN/50% H2O/0.01% TFA 
(v/v/v). 0.5μL of matrix was spotted on a target followed by an equal volume of the synthetic 
peptides or reaction mixtures. The matrix and samples were gently mixed with a pipette and let 
dry under ambient air circulation to co-crystallize. 
LC-Electrospray Ionization (ESI)-Ion Trap (IT) MS 
In order to identify neuropeptides from the reaction mixture with more confidence, 
sequence information is needed. Each microbore HPLC fraction of interest, both pre- and post-
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digestion, was analyzed using a CapLC-ESI-IT MS setup. The capillary HPLC system (CapLC, 
Waters Corporation, Milford, MA) was equipped with a Dionex C18 PepMap column (150×0.3 
mm i.d., 3 μm particle size, 100 Å pore size) running at a flow rate of 2.5 μL/min. A binary 
solvent system with different physicochemical properties from the first dimension microbore LC 
(A: 95% H2O, 5% MeOH, 0.1% formic acid and 0.01% TFA (v/v); B: 95% MeOH, 5% H2O, 
0.1% formic acid and 0.01% TFA (v/v)) was used, in order to get different selectivity and 
partition to better separate the peaks. The MS interfaced downstream of the capLC hyphenated to 
ESI-IT mass spectrometry (HCTultra PTM Discovery System, Bruker Daltonics, Billerica, MA). 
Data was acquired under positive-ion mode with detection ranges of m/z 300-1500 and 50-2000 
for MS and MS/MS respectively. Collision-induced dissociation (CID) was the choice for 
MS/MS analysis. The software parameters for data acquisition were set so that during each MS 
scan, two most intense precursor ions were selected for MS/MS analysis, and dynamic exclusion 
is in effect to exclude precursor ions which have been subjected for fragmentation twice within 
one minute. Ions carrying two charges were set to be preferred precursors.  
 
Data Analysis. MALDI-TOF as well as CapLC-ESI-IT-MS data was analyzed using Bruker 
FlexAnalysis and DataAnalysis software packages respectively. The MS/MS data was exported 
from DataAnalysis with the Mascot generic file format (.mgf) and imported to Peaks Studio 
(Bioinformatics Solutions Inc., Waterloo, ON, Canada) sequence analysis platform. De novo 
sequencing was performed automatically using Peaks Studio with mass tolerance of ≤0.3 Da for 
MS and ≤0.5 Da for MS/MS, and searched against the in-house Aplysia prohormone database 
(data not published). Common PTMs such as amidation, disulfide bond formation, and N-
terminal pyroglutamate were included.  
 
Ion Mobility Mass Spectrometry.The peptides are synthesized using solid phase method and 
purified to 90-95% by HPLC by the Protein Sciences Facility, University of Illinois (Urbana, IL). 
The concentration is 1 mg/ml in H2O. We provided 20 μl of each sample for the demo lab in 
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Waters Corporation. Barbara Sullivan, a Senior MS Applications Specialist performed the demo 
experiments. We obtained the data from Waters on March 26, 2010. The SYNAPT™G2 
HDMS™ Q-TOF instrument was operated in the positive ion mode, scanning m/z 100-1000. 
Resolution mode was used. Other instrumental parameters are as follows: cone=30V, 
capillary=2.5, source temp=80°C, scan time=1 sec. Samples diluted to 500 fmol/μl in 50% ACN 
with 0.1% formic acid) and was infused at 2μl/min. Sigma reverse peptides GRGDS and SDGRG 
were used as standards to test the resolution of IMS, and both were separated with nearly baseline 
resolution with drift time of 2.56 milli secs and 2.75 milli secs respectively. 
 
5.4 RESULTS 
5.4.1 Enhanced Aminopeptidase Digestion Method  
A majority of DAACPs have shown greater or more prolonged physiological effects than the all-L 
epimers, through stabilizing secondary structures such as reverse beta turns;4 the modified 
structures also allow slower digestion by exo-peptidases than all-L forms. Our group have shown 
that NdWFa, a DAACP initially isolated from Aplysia kurodai, cannot be digested by 
Aminopeptidase M;1 the Platypus C-type natriuretic peptide also has shown resistance to 
digestion by this enzyme.7 
Conventionally, Aminopeptidase M (Membrane Alanyl Aminopeptidase, mAAP, EC 
3.4.1.2) has been used for peptide sequencing, due to its wide range of specificity towards most 
L-amino acids. This enzyme selectively digests L- instead of D-amino acids.8 Based on such 
earlier studies, our group demonstrated that neuropeptides containing a D-amino acid at the 2nd 
position can be discriminated from all-L peptides through such digestions. In a proof-of-concept 
experiment, a known DAACP, NdWFa, was identified even with the presence of several orders of 
magnitude higher abundance of other peptides in a sample extracted from the abdominal ganglia 
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in Aplysia californica.1 Here, this work is extended to identify DAACP candidates from Aplysia 
CNS using a workflow comprising several separation and MS techniques. 
 
Method Optimization and Validation. The goal is to test and optimize Aminopeptidase M (APM, 
3.4.11.2)9 method for its specificity on digesting non-DAACPs in a complex sample and retaining 
known DAACPs.  
There are several challenges associated with this goal: The first one is specific N-terminal 
digestion is crucial to discriminate between peptides with or without D-amino acids near the N-
terminal, because otherwise DAACPs can be digested from the other end. For example, a 
surprising C-terminal digestion activity of our commercial aminopeptidase was uncovered, and 
this non-specific activity of C-terminal digestion allows DAACPs to be degraded from the 
“wrong end” and produces false-negative results.  
The second challenge comes from using MALDI MS for the detection of digested crude 
samples; and therefore, this procedure requires the digestion mixture to be compatible with 
MALDI MS. Four different buffers for Aminopeptidase M digestion have been described in the 
literature, including 50 mM ammonium bicarbonate, 200 mM sodium phosphate, 10 mM 
ammonium acetate, and Tris-HCl-NaCl buffer. Tris-HCl-NaCl buffer was found to have least 
interferences with MALDI detection (data not shown), and was used for subsequent 
experiments.Previous data has shown great promise for stereospecific digestion using 
Aminopeptidase M. As shown in Figure 5.1 digestion curves plotted using quantities measured 
with HPLC show that NdWFa level did not change in given time, whereas YdAEFLa and 
angiotensin level declined and eventually disappeared in 24 h.1 Time constants can be calculated 
assuming exponential decay, showing half-life NdWFa>YdAEFLa>angiotensin. 
It would have been expected that YdAEFLa has similar resistance with NdWFa, but was 
digested. One of the reasons may be the presence of non-specific activities such as 
carboxypeptidase activities in the enzymes, and there’s no evidence showing commercial APM 
was free of carboxypeptidase and trypsin activities; while, NdWFa remain undigested despite of 
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possible digestion from the C-terminal because the D-residue is located in the middle of the 
peptide. Nonspecific activities can lead to inability to identify some unknown DAACPs, leading 
to losses of DAACPs. 
To address this issue, the use of a carboxypeptidase inhibitor was explored. 
Benzylsuccinic acid is one of the most effective inhibitors of carboxypeptidase A.10 It acts as a 
competitive inhibitor with Ki =4.5(±0.8) * 10-7 M by mimicking the leaving group in C-terminal 
peptide hydrolysis. Keeping the same condition with what was described in the Material and 
Methods section, benzylsuccinic acid was pre-mixed with the enzyme in the inhibition group, 
with the same volume of extra buffer added instead in the control group. The substrate mixture 
contains NdWFa, YdAEFLa and angiotensin. The two groups both showed digestion of 
Angiotensin in 2 d, indicative of peptidase activity, but marked difference in YdAEFLa digestion 
(Figure 5.2). With the use of the carboxypeptidase inhibitor, the inhibition group didn’t show 
significant degradation of YdAEFLa for at least 8 d, while in the control group YdAEFLa totally 
disappeared at 8 d. Although the actual contamination by carboxypeptidase activities in 
commercial enzymes is yet to be assessed, the potential of improving N-terminal digestion 
specificity with this method is worth further exploration. If it is evident that sequential N-terminal 
residue removal can be achieved with the use of this inhibitor, screening for longer DAACPs can 
be more efficient.  
Next, since DAACP signals are usually suppressed by abundant peptides in a crude tissue 
sample, the ability of APM to eliminate large quantities of interfering all-L peptides is verified. A 
small amount of synthetic NdWFa was mixed with an abdominal ganglia extract, and its 
concentration was carefully adjusted to a very low level, so that initially it was barely detectable 
with mass spectrometry. Over time, NdWFa peak became more prominent, and finally one of the 
most dominant signals (Figure 5.3). This result indicates the ability of this enzyme to overcome 
sample complexity and reveal an initially low-abundant DAACP peak.  
Using Aminopeptidase M as the discovery-enabling agent, we validated the slow 
digestion of DAACPs in a mixture of naturally existing peptides. With this, MALDI as well as 
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ESI-MS will be used as complementary techniques to discover neuropeptides resistant to 
enzymatic digestion.  
The abdominal ganglia from two animals were taken and peptide extracts were 
parepared. Fifteen fractions from an initial HPLC separation were collected and each was 
subjected to APM digestion. Shown in Figure 5.4 is a time course digestion of fraction 1. Several 
peptides observed at the beginning were digested and the signals became weaker with time. In 
comparison with them, a peak (m/z=464.9) appeared at a later point, with the mass and the 
isotopic distribution matching the standard NdWFa peptide. This result agrees well with previous 
data obtained with ESI-MS.1 
NdWFa is the only known DAACP in A. californica,11 which was first isolated in a 
related species, Aplysia kurodai. Even though immunocytochemistry studies showed R3-13 cells 
in A. kurodai were NdWFa-positive cells,12 from our experience NdWFa can only be located in a 
small cluster of neurons in the ventral surface of the abdominal ganglion from A. californica, so 
the signal should be low. Therefore, the detection of the NdWFa peak using this method clearly 
indicated that this method was useful for screening for enzyme-resistant peptides. Several other 
peaks showing resistance to enzymatic digestion, for example m/z 647.3, and m/z 1324.1 can also 
be considered putative DAACPs. 
 
A Workflow Based on the Enzyme Method to Screen for DAACP Candidates. With the 
modified digestion and detection methods, screening was performed as the scheme shows in  
Figure 5.. After peptide extracts are fractionated with microbore HPLC to reduce the chemical 
complexity of the sample, each fraction are subjected to enzymatic digestion and two detection 
methods are used to analyze post-digestion mixtures, MALDI-TOF MS characterization and 
CapLC-ESI-IT-MS sequencing.  
Two types of CNS tissues from Aplysia were used in these experiments, the Pedal-Pleural 
ganglia and the abdominal ganglia. Peptide extracts from these ganglia were fractionated and 
each fraction was analyzed with LC-MS/MS and MALDI MS after digestion to identify peptides 
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that remained in the mixture after 24 h of digestion. After several replicate experiments for each 
ganglion, a few neuropeptides were detected in post-digestion mixture in a reproducible manner.  
A list of identified neuropeptides with confidence scores was generated from Peaks 
Studio and the criteria for neuropeptide identification was set to be 90%. The lists from post-
digestion samples of the same ganglia were compared and the resistant peptides in common were 
chosen for further analysis.  
APM, also named leucine aminopeptidase and microsomal alanyl aminopeptidase, has a 
wide substrate specificity except proline.9 Prior studies indicated APM’s inability to digest certain 
peptides such as CCK-8, GRP-10, somatostatin-14, substance P, and VIP was because these 
peptides contain N-terminal acidic residue, or disulfide bond.13 We also know that N-terminal 
pyroglutamylation protects the N-terminal of a peptide from being digested by peptidases,14 and 
therefore can constitute a false-positive. Therefore, some LAACPs may appear resistant to APM 
digestion. 
The above-mentioned peptides need to be considered separately for the possibility of 
being DAACPs. A list of putative DAACPs will be subjected to chiral amino acid analysis once 
peptide fractions are obtained. In the abdominal ganglia, in 3 out of 5 trials, peptide SVLTDFKD 
(924.5 Da) from the R3-14 prohormone was resistant to digestion; in pedal-pleural ganglia, in 2 
out of 3 trials, Buccalin B GLDRYGFVGGL(a) (1153(2).6 Da) was detected. These two 
neuropeptides, together with several other peptides of interest including β-BCP (1009.3 Da), 
acidic peptide (2959.6 Da), FMRFa (599.4 Da), proCerebrin LAARLI (656.4 Da) are now 
considered DAACP candidates. These peptides will be subjected to further analysis with methods 
to be described in Chapter 6. 
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5.4.2 Ion Mobility Spectrometry in Screening for D-Amino Acid-
Containing Peptides  
In this study, we determined the feasibility of separating pairs of epimers including Y(l/d)AEFLa, 
F(l/d)MRFa, G(l/d)FAD, and N(l/d)WFa using two IMS instruments, the Waters SYNAPT-G2 
with its ion-mobility feature and a custom-built IMS with 2-meter drift tube in the Clemmer 
group. The objective was to determine how well IMS can be for separating stereoisomers based 
on their subtle differences in their cross-sectional areas.  
Two pairs of synthetic peptide epimers were separated on the SYNAPT G2 system. As shown in 
Figure 5.6 through Figure 5.8 Y(l/d)AEFLa and F(l/d)MRFa were both separated with drift time 
differences of around 0.5 msec between the all-L and the D-amino acid-containing forms.  
N(l/d)WFa and G(l/d)FAD were not distinguishable on the drift time axis with current conditions. 
The peptide epimers co-elute in roughly one peak with only slightly distorted peak shapes showing 
signs of co-elution.  
In collaboration with Clemmer group, we have attempted separations using the same set of 
peptide epimers. Figure 5.8 shows the separation of NWFa and NdWFa. These two peptides are small 
and have only very subtle structural difference, and no baseline resolution has been observed. Figure 
5.9 is the separation of GFFD and GdFFD. These peptides form clusters in the electrospray process, 
and monomers have only very small differences in drift time. Interestingly, dimers and tetramers can 
be separated.  
These results demonstrate the IMS method can be useful in screening for structural heterogeneity 
between peptide epimers, assuming both epimers co-exist in the same sample and are above detection 
limit. This added dimension of separation provides opportunity which is previously unavailable with 
conventional MS methods.  
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5.5 CONCLUSIONS AND FUTURE DIRECTIONS 
Given the spatial and chemical complexity of brain tissues, it is necessary to focus on testing a 
subset of the entire neuropeptide contents. Here two approaches were highlighted, one that was 
used on complex samples, and the other is a test case. There are several advantages of using the 
enzyme digestion method, including the wide substrate specificity toward L-amino acids. More 
importantly, this method is particularly suitable for biological samples which contain peptides 
spanning a large dynamic range of concentrations because the Aminopeptidase M can remove the 
interference of highly abundant all-L form peptides. This feature makes it especially 
advantageous when interfacing with MS because it addresses the concerns about analyte 
competition for ionization and detection in a mass spectrometer. The enhancement of this method 
was important for reducing false negatives, i.e., minimizing the chance of missing some real 
DAACPs in digestion.  
The IMS method is less well developed, and has several assumptions. For example, it works 
well when both epimers are present. It is quick and direct, because it doesn’t require substantial 
manipulation of samples or harsh procedures that will change the sample composition, and 
therefore introduces less complexity in data interpretation and verification.  
These two methods complement each other and serve to generate a list of peptides to be 
tested in the next stage, chiral amino acid analysis which will be detailed in Chapter 6.  
There’s room for improvement of these methods. So far we’ve only considered the 
neuropeptides that may contain a D-amino acid near the N-terminus. Although neuropeptide 
DAACPs discovered to date all have the same consensus site of isomerization, to be more 
thorough, we can also make minor modifications to current workflow for it to be used with 
carboxypeptidases and screen for peptides that may contain D-amino acids near the C-terminus. 
Similarly, some structural patterns may result in enzyme resistance as well, and they can be 
selectively excluded.  
Opportunities do exist to enhance resolution of epimer separation on IMS, including infusing 
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chiral gas modifier or co-spraying chiral selectors and increasing buffer gas temperature.  
Another method that is not discussed here is to characterize split peaks on LC-MS, i.e., two 
peaks with the same m/z resolved on LC. Our group has observed such phenomena for acidic 
peptide from Aplysia, a rat circadian rhythm-related peptide in the suprachiasmatic nucleus 
(SCN), and other peptides yet to be characterized. This method, combined with the other two, can 
make the search for DAACP candidates more thorough and this information can be obtained from 
peptidomics studies that are a major expertise area of the Sweedler group. 
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FIGURES AND TABLES 
 
 
 
Figure 5.1. Stereospecific digestion with Aminopeptidase M. Digestion of a mixture of D-amino 
acid-contining NdWFa, YdAEFLa, and an all-L peptide Angiotensin show the relative enzyme 
resistance of D-amino acid-containing peptides. Adapted and used with permission from Ref 1. 
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Figure 5.2. MALDI mass spectra showing digestion of mixtures of synthetic peptides with or 
without carboxypeptidase inhibition. In a mixture composed of NdWFa, YdAEFLa and 
angiotensin, commercial Aminopeptidase M used alone digests YdAEFLa in about four days, 
while enzyme pre-mixed with benzylsuccinic anhydride, a carboxypeptidase inhibitor, doesn’t 
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show significant digestion of YdAEFLa. In both situations, angiotensin can be digested. The 
upper spectrum illustrates the result when the enzyme is used alone and the lower one shows 
when the enzyme is premixed with inhibitor.  
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Figure 5.3. In a biological sample as complex as the abdominal ganglia extract, a small amount 
of added NdWFa standard can be distinguished. The concentration of NdWFa was made so low 
that it is not detectable initially (shown in the first trace, peaks in the lower mass range do not 
match NdWFa), but after 18 hours (lower trace) of digestion, NdWFa peak is higher in relative 
intensity. Stars in the upper trace show identifiable neuropeptides, and the star in the lower trace 
points at the NdWFa peak.  
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Figure 5.4. MALDI spectra showing time-course digestion of natural abdominal ganglia extract 
shows the m/z 464.9 peak matching NdWFa. Several known peptides disappear with time, while 
putative NdWFa peak appears after abundant peptides are removed. Stars in the first two traces 
represent known peptides, and in the lower two traces represent putative NdWFa.
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Figure 5.5. Workflow of the enzyme-aided high-throughput screening. The process starts from 
sample preparation. Aplysia are dissected and the CNS tissues are removed from the body. 
Different ganglia are prepared separately, i.e., abdominal ganglia, buccal ganglia, cerebral 
ganglia, pedal and pleural ganglia. Extracts are made and are fractionated by HPLC. Each 
individual fraction is digested using APM, and two detection methods are used including MALDI 
MS for fast and sensitive detection and LC-ESI MS/MS for sequencing. 
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Figure 5.6. Separation of YAEFLa and YdAEFLa with IMS on SYNAPT-G2. Both peptides had 
drift times of 1.57 msec and 2.1 msec respectively. With driftscope display, two bands can be 
observed with m/z 641.3.   
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Figure 5.7. Separation of FMRFa and FdMRFa with IMS on SYNAPT-G2. Both peptides had 
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drift times of 3.1 msec and 3.6 msec respectively. With driftscope display, two bands can be 
observed with m/z 599.3.   
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Figure 5.8. Separation of G(l/d)FAD and N(l/d)WFa pairs with IMS on SYNAPT-G2. Both 
peptide pairs didn’t show significant differences in drift time. With driftscope display, only one 
band was detected for each pair..   
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Figure 5.9. IMS detection of various peaks from NWFa. [NWFa + H]+ and [2NWFa+3H]3+ 
were both detected. NWFa and NdWFa have some subtle differences in drift time. 
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Figure 5.10. Drift distribution of GFFD (blue), GdFFD (red), and a mixture of both (black). 
mass range m/z 761-765. It appears that there may be separation of three dimers (all +1 charge) 
based on this distribution. There may also be separation of tetramers but that distribution is too 
complex to properly determine with the present data. 
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CHAPTER 6  
 
CHIRAL AMINO ACID ANALYSIS FOR 
NEUROPEPTIDES 
Notes and Acknowledgements 
This chapter describes development and application of amino acid analysis techniques for 
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DA018310 to the UIUC Neuroproteomics Center on Cell-Cell Signaling. 
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6.1 ABSTRACT 
As described in Chapter 5, screening methods are required to identify neuropeptides from 
complex neural tissue samples which potentially contain a D-amino acid. Based on the work in 
Chapter 5, a list of neuropeptides has been compiled based on relative resistance to 
aminopeptidase M digestion.  The next step is to confirm the presence of the D-AA in these 
peptides.  The goal of this step is to eliminate misidentifications from the enzymatic screening, 
confirm the presence of a D-amino acid residue, and identify the isomerized amino acid.  
The results of the screening produce lists of literally dozens of peptides to be tested. 
Thus, the D-AA approaches should be generally applicable, robust and fast so that each candidate 
can be analyzed for its D-AAs. Given these requirements, amino acid analysis instead of intact 
peptide analysis appears to have a number of advantages.  
Several methods that have been adapted for chiral amino acid analysis are described in 
this chapter, including chiral Edman degradation, capillary electrophoresis (CE), and liquid 
chromatography-tandem mass spectrometry-multiple reaction monitoring (LC-MS/MS-MRM). 
The last approach is described in more detail and preliminary data from analyzing biological 
samples will be introduced as well.  
 
6.2 INTRODUCTION 
Reversed-Phase HPLC is often used to confirm chirality of a peptide by demonstrating 
co-elution of the endogenous form with the proposed synthetic D-amino acid-containing form.1-2 
Bioassays and analytical methods such as CE, NMR and MS can also be used to confirm the 
chirality of intact peptides by comparing the native biological peptides with synthetic standards 
(refer to Chapter 2 for a comprehensive review of these methods and their application).3 At this 
stage of DAACP identification when dozens of candidates need to be tested, it is important to 
establish a generally applicable method. Breaking down peptides into amino acids and analyzing 
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the chirality of amino acid components is a more efficient way of eliminating false positives 
generated from the initial screening.  
Acid hydrolysis of peptides and proteins has been one of the most often adopted methods 
to digest peptides into amino acids.1 It is quick and easy compared to the sequential release of 
amino acid residues from protease/peptidase digestion. However, it does lose the sequence 
information. In order to partly compensate for this lack of sequence information, working with 
organisms using animals with well-studied peptidomes makes sense. Within the Sweedler group, 
we have characterized the peptidomes of the sea slug Aplysia californica (Sweedler group, 
unpublished), the honey bee Apis,4-5 the sea urchin, the song bird,6 and several functionally 
important brain regions in rat such as the supraoptic nucleus (SON)7 and the suprachiasmatic 
nucleus (SCN).8 Therefore, we have the tools and knowledge to collect sequence information 
from a peptide sample isolated from many species. This serves as a solid knowledgebase to go 
back to when acid hydrolysis doesn’t generate enough information on peptide sequence. This 
combination promises a more complete characterization of the peptide sample.  
Compared to acid hydrolysis, chiral Edman sequencing promises to generate both 
sequence and chirality information. The chiral Edman degradation method uses a fluorescent 
chiral tagging reagent, 4-(3-isothiocyanatopyrrolidin-1-yl)-7-(N,N-dimethylaminosulfony l)-2,1, 
3-benzoxadiazole [R(-)-DBD-PyNCS] developed by Toyo’oka and Liu in 1995.9 This method is 
especially suitable for uncharacterized peptides, and complement the above mentioned amino 
acid analysis method.  
There are two caveats with acid hydrolysis: incomplete digestion and racemization. 
Racemization, in particular, results from side-chain incorporation at the Cα position. To achieve 
an optimized condition, we have carried out both liquid-phase and vapor-phase acid hydrolysis 
and used CE measurement as the output for its sensitivity and quantitative nature. Racemization 
happens with chiral Edman degradation as well. One way to address this issue is to use deuterium 
chloride (2HCl or DCl).10 DCl-hydrolysis-induced racemization will result in incorporation of 2H 
instead of H from HCl, which will be discriminated by mass spectrometry-based detection 
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techniques. This method is adopted in LC-MS/MS-MRM analysis of peptide hydrolysates.  
In what follows, the individual approaches are independently described, both in terms of 
the experimental details and results.  After all results are presented, an overall conclusion and 
summary of the approaches are presented.  While it may appear that too many approaches are 
used, this is partly because the optimum methods were not known before the experiments were 
undertaken and the simultaneous investigation of several approaches enabled a faster approach to 
optimum conditions as well as allowed more robust series of protocols to be developed. 
 
6.3 CAPILLARY ELECTROPHORESIS ANALYSIS OF 
PEPTIDE HYDROLYSATES 
 
6.3.1 Material and methods 
Materials. Constant boiling hydrochloric acid (6N, 1 mL ampules for liquid-phase hydrolysis, 
and regular HCL in bulk for vapor-phase hydrolysis) and a reusable vacuum hydrolysis tube for 
the liquid phase hydrolysis were purchased from Thermo Scientific (Pierce Protein Research 
Products, Rockford, IL). A dry block heating system was used to control and maintain the 
reaction temperature. Water was purified from a Milli-Q system (Millipore, Bedford, MA). 
  
Acid Hydrolysis Procedures. Liquid phase acid hydrolysis (108 ºC for 14 h) was performed 
following the protein/peptide hydrolysis protocol available on Thermo Scientific’s website. A 
general procedure is as follows: 
Peptide samples were carefully added to the bottom of the vacuum hydrolysis tube using a 
glass Pasteur pipette, and the PTFE plug was screwed to secure it in place but to leave a little gas 
passageway. 1 mL high-purity HCl was added to the bottom of the hydrolysis tube. The side arm 
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of the tube was connected to vacuum through a three-way stopcock which also connects to 
nitrogen gas. This allows easy switch between vacuum source and inert gas source. Then the 
vacuum was applied to remove oxygen and the PTFE plug was tightened just enough to seal the 
tube. Once done, vacuum was carefully released and the plug was removed after the tube cools 
down. Hydrolysates were transferred to other containers for further analysis. 
Vapor phase (150 ºC for 30 min or 2 min) hydrolysis was performed in a TEM vapor-phase 
microwave acid hydrolysis system (Mathews, NC). A 45-mL vessel was used to hold up to 10 
samples in the dried form contained in glass reaction microvials. 20 mL 6M HCl is used for each 
hydrolysis experiment. The hydrolysis is programed to take 5 min at 150 ℃. Before starting the 
hydrolysis, the vessel was evacuated to remove air (for 30 s) and purged with nitrogen (for 5 s) 
using a 3-way stopcock. This alternation was repeated for 5 times and the vessel was evacuated 
again (for 1 min). After the program starts, it usually takes 10-15 min to achieve the target 
temperature. After finishing the 5-min hydrolysis, it takes about twenty minutes to cool down to 
about 70 ℃. Then the vessel is opened and the hydrolysis tube is taken out to evaporate in 
SpeedVac (Savant Instruments Inc., Farmingdale, NY) in order to remove any HCl condensation 
that might have accumulated in the microvials.  
 
Capillary Electrophoresis. For all experiments, a commercially available P/ACE MDQ with LIF 
detector (Beckman Coulter, Fullerton, CA) and fused-silica capillary (Polymicro Technologies, 
Phoenix, AZ) were used. A diode laser emitting 442±7 nm (CVI Melles Griot, Carlsbad, CA) was 
used as excitation source for LIF. The laser was coupled with an optic coupler (OZ Optics, 
Ottawa, Ontario, Canada) to send laser light into fiber optics (OZ Optics). Output power of the 
laser at the end of the fiber optics was adjusted approximately 3 mW before the fiber optics was 
connected to P/ACE MDQ. A band-pass filter of 490±15 nm (Omega Optical, Brattleboro, VT) 
was set before a photomultiplier tube of the LIF detector to collect fluorescence signals. 
After hydrolysates are evaporated to dryness in SpeedVac, the residues were suspended in 
100 mM borate buffer (pH=9.5) before NDA derivatization. 1 µL of the sample was derivatized 
 143 
 
with 2 µL of NDA solution (10 mM in methanol) and 2 µL of sodium cyanide solution (20 mM in 
100 mM borate buffer, pH=9.5). This mixture was then incubated in dark at room temperature for 
1 hour to complete the reaction. For CE-LIF measurements, the derivatized mixtures were diluted 
into appropriate concentration by 100 mM borate buffer at pH=8.5. 
Before experiments a new capillary was initiated by sodium hydroxide (0.1 M) for 25 min. 
For chiral amino acids separations (except aliphatic amino acids), a fused-silica capillary (80 cm 
total length, 70 cm to detection window, and 75 µm of i.d.) was used. The separation buffer 
consisted of 200 mM borate, 60 mM sodium deoxycholate (SDC), and 40 mM β-cyclodextrin (β-
CD) at pH=9.5. The sample was injected by pressure of 0.5 psi for 5.0 s and was separated by 27 
kV normal polarity. After each separation, the capillary was rinsed by methanol (40 psi for 1 min) 
followed by separation buffer (30 psi for 1 min). For aliphatic amino acid separations, a fused-
silica capillary of 60 cm total length, 50 cm to detection window, and 50 µm i.d. was used. The 
sample was injected by pressure of 0.5 psi for 5.0 s and was separated by 20 kV reverse polarity. 
The separation buffer of the capillary inlet end contained 4 wt% sulfated-β-CD in 25 mM 
phosphate at pH=2.2 and the separation buffer of the capillary outlet end contained 50 mM 
phosphate at pH=2.2 (hereafter, these inlet and outlet buffers are referred as acidic separation 
buffers). After each separation, the capillary was washed with methanol (40 psi for 1 min) 
followed by the inlet buffer (30 psi for 1 min). 
6.3.2 Results 
Conditions for acid hydrolysis were optimized using synthetic peptide FMRFa as a model 
and CE as the output. NDA-labeled amino acids were separated with β-CD added as a CMPA in 
the separation buffer. Table 6.1 shows the quantification of racemization at each residue under 
three different conditions, liquid phase (108 ºC for 14 h), long vapor phase (6M sequencing-grade 
HCl, 150 ºC, 30 min), and short vapor phase (6M sequencing-grade HCl, 150 ºC, 3min).  
The vapor-phase method is generally considered “cleaner” than the liquid-phase method 
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because only HCl vapor makes contact with the samples, which minimizes background 
contamination from the HCl; it allows high throughput as well because reaction takes place in a 
sealed vessel holding up to 10 microvials containing dried samples in a microwave hydrolysis 
apparatus. Each cycle only takes minutes, which has significant advantage over the liquid-phase 
method. Racemization rate is comparable between liquid-phase and 2-min vapor-phase 
hydrolysis. Based on this result, we decided to pursue the 2-min vapor-phase method. 
A good demonstration of the CE analysis of hydrolysates is shown in Figure 6.1. It is the 
chiral separation of amino acids generated from 2-min vapor-phase method from the peptide 
GdFFD. This peptide has both L- and D-Phe, which can be baseline separated. This method has a 
very low limit of detection at the attomole range. More importantly, it is very quantitative because 
of the observation of 1:1:1:1 ratio of G, dF, F and D residues measured in peak area. There is 
some racemization of Asp which was expected.  
Two of the DAACP candidates from the screening step were analyzed with this method. 
FMRFa (FMRF-amide, m/z 599.3) and Buccalin B (GLDRYGFVGGL-amide, m/z 1152.6) 
purified with two-stage HPLC. Unfortunately, all residues were found to be in the L-form (data 
not shown).  
A drawback that we have experienced with this method is that it can take more than one 
CE experiments to establish a method that separates the L and Damino acid components. While 
several approaches have been reported to resolve all amino acid pairs using CE (REF), to date, 
our separations did not perform a complete racemic separation. Because of this, the approach is 
time-consuming when analyzing relatively long peptides.  
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6.4 CHIRAL EDMAN DEGRADATION METHODS FOR 
SIMULTANEOUS DETERMINATION OF PEPTIDE 
SEQUENCE AND CHIRALITY  
 
6.4.1 Material and methods 
Materials. DBD-PyNCS was obtained from Tokyo Chemical Industry Co. (TCI) America 
(Portland, OR). Acetonitrile (ACN), Trifluoroacetic acid (TFA), Pyridine, n-Heptane, 
Dichloromethane, Ethyl acetate, acetone and HPLC-grade water were obtained from Sigma 
Aldrich (St. Louis, MO). Water was purified from a Milli-Q system (Millipore, Bedford, MA). 
 
Chiral Edman Sequencing. The derivatization procedure follows previously reported protocol.11 
First 10 mM DBD-PyNCS 100 μL in H2O/CH2CH/Pyridine (2:1:1, v:v:v) is prepared, mixed 
with dried peptide sample (50 μL, 1mM), heated at 65 ºC for 60 min, and washed with 200 μL n-
Heptane/Dichloromethane (8:2, v:v) twice to remove excess labeling reagents. The organic phase 
is discarded, and the aqueous phase is dried and kept for the next step. 100 μL TFA was added to 
the dried aqueous phase, heated at 55 ºC for 1 min, and dried. An extraction step was carried out: 
100 μL water and 200 μL Ethyl Acetate were added to the residue, mixed and centrifuged at 3000 
rpm for 2 min twice. The aqueous phase from this step contains residual peptide with removed N-
terminal amino acid was then dried and stored for the next cycle. The organic phase was dried, 
and 100 μL of 50% TFA was added to it, heated at 65 ºC for 30 min, and dried. Organic and 
aqueous phase was separated by repeating the above-mentioned extraction step. The aqueous 
phase was discarded, and the organic phase was dried and reconstituted in ACN for HPLC 
analysis.  
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Experimental Design and Results Interpretation. To sequence a peptide, even only the three N-
terminal residues, requires more than one cycle of Edman reactions, each being a multi-step process. 
One complete cycle includes the coupling of the sequencing reagent and the N-terminal of the peptide, 
a cyclization/cleavage step with TFA to cyclize the N-terminal and to remove the labeled terminal 
residue from the peptide, and a conversion of this residue to the liberated phenylthiohydantoin- (PTH-
) amino acids. Due to the complexity of the procedure, the presence of multiple reagents, solvents, and 
generation of by-products can also be detected in HPLC analysis and interfere with peak 
identification. Therefore, including controls is essential to un-biased interpretation of the results.  
 A blank sample containing only HPLC-grade water is always run before any sample to ensure 
no contamination or carry-over in the system. A control sample refers to one from a blank reaction 
which contains no peptide sample to start with but goes through the whole labeling process in parallel 
with the real peptide being sequenced. A control is prepared at the beginning of the first cycle and is 
treated as a bona fide peptide sample, and this provides the control for  potential contaminations and 
interference introduced by reagents or reactions. The comparison between the controls with the 
samples tells us which peak is the currently released residue. 
 The peak assignments from in Figure 6.3 were done by comparing sample runs with controls. 
Additionally, labeling experiments with free amino acids corresponding to the sequenced residues 
were also carried out to confirm the retention time.  
  
6.4.2 Results 
The goal of chiral Edman sequencing is to simultaneously get sequence and chirality 
information, which is especially useful for uncharacterized peptides. This method was performed 
manually, and RP-HPLC with UV detection was used to analyze derivatized amino acids freed 
from the N-terminus.  
However, these chromatograms are difficult to interpret. In addition to multiple reagent 
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peaks, preview and review of residues from the previous and the following cycles were detected. 
Extra peaks interfere with the detection of the amino acid currently being sequenced, posing 
challenges for separation and peak assignment.  
 Both the manual and the automated methods were developed with the use of a pair of 
synthetic peptides, NWFa and NdWFa. As low as 1-2 pmol of these peptides can be detected with 
chiral resolution up to three cycles.  
 These multi-step analyses involving solvent extraction and washes cause a decrease in 
yield with the progression of sequencing. With 1-2 pmol of sample, it can proceed up to three 
cycles. More importantly, the manual peak assignment is challenging and unreliable sometimes. 
To increase throughput and reproducibility, an automated Edman sequencer was used with 
redesign of instrumental protocols including reagent and solvent delivery based on the different 
requirement for the chiral Edman reaction. In this case, the ProciseTM Protein Sequencing System 
which normally uses phenylisothiocyanate (PITC) as the tagging reagent was used. The major 
changes of instrumental protocols are as follows: 
DBD-PyNCS was dissolved in 3.5 mg/ uL in ACN (R1) was loaded to cartridge instead 
of the regular Edman reagent PITC dissolved in heptane. Due to less harm of residual ACN than 
residual heptane to the following steps, Dry Cartridge time was shortened from 30 to 20 s. The 
coupling base N-methylpiperidine in MeOH-containing water (R2B) was then delivered twice to 
the cartridge, each 700 s. This is shorter than the regular 900-s deliveries of regular R2B, because 
this coupling step deprotonates the free amino groups for reaction with the labeling reagent, 
which will increase the chance of Asp and Glu residues being modified by reaction of the side 
chain carboxylic acid group with aniline. Post-coupling wash was also important to remove 
coupling reagents and by-products. This step won’t result in loss of residues because the samples 
were immobilized on the PVDF membrane in the initial steps. Therefore, intense wash was done 
with a combination of solvents including n-butylchloride, ethyl acetate, and ACN for multiple 
times each. TFA (R3) was then delivered for 10 sec and to allow incubation at 48 ºC for 300 s. All 
the other steps remain unchanged from PITC sequencing protocols. 
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 The racemization of certain amino acids, especially Asp and Pro can happen at two of the 
three steps in the Edman reaction, cyclization/cleavage and conversion.12 Therefore, artificial 
racemization is still observed which can confuse the identification of naturally-occurring D-amino 
acids in peptides.  
 
6.5 USING LIQUID CHROMATOGRAPHY-MASS 
SPECTROMETRY/MASS SPECTROMETRY-MULTIPLE 
REACTION MONITORING (LC-MS/MS-MRM) METHOD 
TO IDENTIFY D-AMINO ACIDS FROM PEPTIDE 
HYDROLYSATES   
 
In this section, a high-throughput LC-MS/MS-MRM method is introduced as a chiral amino acid 
analysis technique for DAACP discovery. This hyphenated method allows separation of all amino 
acid enantiomers within a short gradient even without complete separation in the LC phase, and 
thus is suitable for measuring the amino acid composition of peptides from complex biological 
samples. An introduction will be followed here because this is the most promising approach that 
we have tested so far for the purpose of identifying novel DAACPs. 
In recent years, hyphenated approaches such as LC-MS have been heavily used to 
analyze complex samples in a high-throughput fashion, due to its separation capability in the front 
end and the identification capability by MS.5, 13-14 A wide range of chromatographic techniques 
are available to target proteins, peptides and metabolites. The rapidly evolving  MS 
instrumentation provides increasingly high sensitivity and resolution, as well as better automation 
to enable high-throughput analysis.  
Multiple Reaction Monitoring (MRM, also known as Selected Reaction Monitoring) 
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functionality is a valuable addition to the LC-MS/MS techniques, which allows simultaneous 
detection of multiple compounds and provides excellent quantitative capabilities.15-17 It has been a 
favored technique for target-based metabolomics and proteomics studies, in which precursor-to-
product ion transitions are monitored during an MS run in a triple quadrupole instrument.18-19 As 
is shown in Figure 6.4, a triple quadrupole mass spectrometer contains three quadrupoles, each of 
which comprising two pairs of circular rods placed in parallel. The first (Q1) and the third (Q3) 
quadrupoles with oscillating electric field act as mass filters, and only ions with certain m/z 
matching the field can travel through to the detector. Q2 is a collision cell where target parent 
ions are fragmented. Both parent and product ions masses need to be provided to establish an 
MRM channel specific to one parent-to-daughter ion transition. Multiple target masses can be 
monitored simultaneously in separate channels due to the fast scanning speed of quadrupoles, and 
therefore, it adds to another dimension of separation that allows at least qualitative analysis of 
even incompletely separated compounds from LC.16 LC-MS/MS-MRM methods have been used 
to analyze complex mixtures of metabolites such as amino acids, sugars, nucleic acids and 
organic acids. More than three orders of linearity have previously been achieved for 80% of over 
200 compounds with LOD as low as below 200 pictogram/mL.20  
For our application, chiral resolution is needed, so we used the Marfey’s reagent (1-
fluoro-2,4-dinitrophenyl-5-L-alanine amide, FDAA) to derivatize amino acids before LC 
separations.21 This classic labeling reaction (Error! Reference source not found. 6.5) only takes 
several simple steps and the reaction is quantitative. Peptide hydrolysate contains many different 
amino acids and incompletely digested peptides, which can all be labeled by Marfey’s reagent. 
Some of the amino acids (e.g. His, Tyr, and Lys) can carry either one of two Marfey’s reagent 
molecules. These possibilities will make data from regular HPLC with UV detection difficult to 
interpret.  
LC-MS/MS-MRM is more suitable to analyze complex amino acid mixtures thanks to 
target-based nature and the added dimension of separation. This method is more sensitive than the 
more conventional detection of Marfey’s reagent-labeled amino acids using LC-MS because 
 150 
 
target-based detection greatly reduces background. This method has previously been used to 
quantify the serine enantiomers in rat brain microdialysate and was validated that it could 
determine concentrations over the range of 10–7500 ng/mL. 22  
 
6.5.1 Material and methods 
Materials. Solvents: acetonitrile (ACN) containing 0.01% trifluoroacetic acid (TFA), acetone and 
HPLC-grade water were obtained from Sigma Aldrich (St. Louis, MO). Other chemicals: 32% 
HCl, sodium bicarbonate were purchased from Sigma Aldrich. Marfey’s reagent (FDAA) was 
purchased from Thermo Scientific (Pierce, Rockford, IL). Water was purified from a Milli-Q 
system (Millipore, Bedford, MA). 
  
Acid Hydrolysis Conditions. Acid hydrolysis conditions are generally the same with those used 
for CE analysis. When DCl is used, it is important to keep DCl away from moisture. Dilution of 
DCl to 6M has to be in D2O. The whole process needs to be fast enough to avoid contamination 
by hydrogen-containing water. 
 
Marfey’s Reagent Labeling. Protocols are slightly modified from the product instruction from 
Pierce Technologies, Inc. (Rockford, IL) to scale down for smaller samples. For standard amino 
acids, 25 μL of 10 mM amino acids were dried in SpeedVac, and 10 μL of 0.5 M sodium 
bicarbonate was added to each tube to resuspend the hydrolysates. 20 μL 1% FDAA in acetone 
was added to each tube, and gently mixed. Incubate the reaction mixture at 40 ℃ for 90 min on a 
shaker. By the time the incubation was done, reaction was stopped and the mixture was 
neutralized by adding 2.5 μL 2M HCl. After degassing stopped, sample was centrifuged to 
precipitate any insolubles, and the supernatant can be analyzed or dilute with 25 mM ammonium 
acetate (pH 5.2) before analysis.  
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LC-MS/MS Conditions. The LC/MS/MS setup is composed of an Agilent 1200 Infinity liquid 
chromatography system (Agilent, Santa Clara, CA), and an Applied Biosystems API 5000 triple 
quadruple mass spectrometer (Applied Biosystems Inc., Framingham, MA). LC-MS/MS-MRM 
experiments were performed with assistance from Dr. Lucas Li in the Metabolomics Center of the 
Roy J. Carver Biotechnology Center at the University of Illinois at Urbana-Champaign. 
A C6-Phenyl column (C6-Phenyl 110A, 100x4.60 mm, particle size 3 μm, Phenomenex, 
Torrance, CA) was used for the LC separations. A binary solvent system was used with A being 
25mM ammonium acetate pH5.2, and B being ACN/0.1% TFA. The 36 min-gradient comprises 
several steps as are shown in Table 6.2. 
To set up the MRM method, direct infusion was used with Marfey’s reagent-labeled 
standard amino acid samples (including 19 naturally occurring L-amino acids, 19 D-amino acids, 
and non-chiral Glycine). Samples were prepared as described above, and diluted 1000 times 
before injection. 2 μL of each sample was injected and they were at approximately the femtomole 
level. 
To maximize sensitivity of this method, instrumental parameters may be adjusted to 
generate the most intense signals. This requires choosing the proper ion polarity mode (positive or 
negative) that generates the most intense parent ion, and ramping for the right declustering 
potential (DP) which gives the best parent ion signal. Under MS/MS mode, the most intense 
product ion is chosen, and the corresponding collision energy (CE) is optimized to obtain the 
highest intensity in product ions. 
Other parameters are listed as follows: Nebulizer gas (GS1) was 50 psi and bath gas (GS2) 
was 60 psi, curtain gas (CUR) was 40 psi, and collision gas (CAD) was set to medium. Source 
temperature (TEM) was 600. In the mass spectrometric data acquisition, dwell time for each 
MRM channel was 20 msec.  
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6.5.2 Results 
Analytical Method Development. Each amino acid standard derivatized with Marfey’s reagent 
was directly infused to the mass spectrometer for tuning. 
First, target masses were selected. For most amino acids, one Marfey’s reagent tagging 
adds an additional 253 mass units to the amino acids; while no significant signals corresponding 
with addition of one Marfey’s molecule were found with tyrosine, lysine and histidine, instead, 
m/z corresponding to addition of two Marfey’s molecules were detected due to additional labeling 
at extra amine groups or reactive hydroxyl groups 23.  
Ionization polarity was optimized for each compound. Declustering potential (DP) was 
60 and -60 volts for the positive and negative modes respectively. Most amino acids were found 
to generate the most intense signals in the negative mode except Arginine and Tryptophan. Q3 
masses and the corresponding collision energies of each amino acid were optimized one by one. 
When two or three Q3 product ions were detected, the most intense peak was selected. L-amino 
acids were used to find the most efficient transition and to optimize the corresponding collision 
energy; however, we did use several D-amino acids to test and the results didn’t differ from the L-
forms (data not shown). Q3 masses and collision energies are listed in Table 6.3.  
Depending on the efficiency of labeling and fragmentation, amino acids do respond 
differently to the MRM detection. Signals were compromised in the cases of Tyr, His and Lys 
likely due to possibilities of carrying both one and two FDAA molecules. 
Baseline separation was achieved for all 19 pairs of amino acid enantiomers (not 
including Gly) in 18 channels within 36 minutes, with slight drift of retention time below 0.3 min 
from run to run. Each pair of amino acids was separated and in most cases with baseline 
resolution except for D-Ile and D-Leu. Leu and Ile have exactly the same m/z, signature fragment 
ions, and collision energies, so they could not be separated into different channels.  
The separation power of LC-MS/MS-MRM method has enabled definitive identification 
of an amino acid enantiomer by retention time and specific transition (channel). A good example 
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is the separation of Glycine and Alanine. These two amino acids have similar retention times 
(<0.1min), but with MRM identifying distinct parent ion and product ion, they can be 
discriminated in two different channels, and quantified separately, which couldn’t have been 
achieved with regular separation methods. 
Figure 6.6 shows chromatograms of different channels from one MRM run showing 
separation of all 39 Marfey’s reagent-labeled amino acid enantiomers. 
Method Validation. A 5-min vapor-phase acid hydrolysis was used to digest peptide fractions, 
and the resulting amino acids were labeled with Marfey’s reagent and analyzed with the LC-
MS/MS-MRM approach. As was mentioned in the Introduction section in this chapter, one way to 
overcome the racemization in acid hydrolysis process, we used deuterium chloride (2HCl or DCl) 
instead of regular HCl.10 DCl-hydrolysis-induced racemization will result in incorporation of 2H 
instead of H from HCl, which will be discriminated by mass spectrometry-based detection 
techniques.  
Before analyzing unknown biological samples, we started with the recently discovered novel 
DAACP, GdFFD, to test the effectiveness of this workflow. As shown in Figure 6.7, in this 
hydrolysis experiment, five samples, including synthetic GFFD, GdFFD, and a biological sample 
containing GdFFD, and two blanks, were put in the same vessel which was evacuated to remove 
oxygen, and went through vapor-phase hydrolysis. Acid hydrolysis and labeling procedures seem 
to be reasonably quantitative for different residues as shown in the case of GdFFD. We observed 
D-Phe in the biological sample, while the GFFD didn’t have any detectable D-Phe in the Phe 
channel. This means that artificial racemization was reduced to below the limit of detection, and 
so it appears the D-Phe from the biological sample was real.  
 
Chiral amino acid analysis on hydrolysates of unknown neuropeptides isolated from Aplysia. 
Figure 6.8 is the mass spectrum of a neuropeptide fraction isolated from Cerebral ganglia from 
Aplysia californica using HPLC. Table 6.4 is the list of peptides which are mass-matched to an in-
house neuropeptide database of Aplysia californica (Sweedler group, unpublished data). The list 
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is organized by descending peak area measured by MALDI MS. The most abundant peptide is 
RLRFH (m/z 728.6), and there are other less intense peaks as well, for example, SVDSDLD (m/z 
750.3) from FMRFa prohormone, and SDAAFLETRHL (m/z 1372.7) from the PRQFVa 
prohormone, etc. Because these assignments are not confirmed by MS/MS sequencing, some 
mass matches are not unique, for example, peak m/z 832.1 can be correlated to three possible hits 
from the neuropeptide database.  
Chiral amino acid analysis of hydrolysates from this fraction is performed. A 39-amino 
acid mixture is also analyzed right after the biological samples to calibrate for retention time. 
Blank injection of HPLC-grade water serves as a negative control and shows no amino acid 
signals (data not shown). The results from the biological sample are shown in Figure 6.7. Most 
amino acid residues identified are in the L-form as can be determined by retention time. The most 
intense amino acid signals include the R, L, F, and H residues from the major component peptide 
RLRFH. Two D-amino acid peaks were detected, D-Asp and D-Trp. These residues could be 
traced back to the mass list of this sample, and the D-Asp is likely to be from the 
SDAAFLETRHL (m/z 1372.7) peptide from the PRQFVa prohormone. Another fact that may 
support this identification is the potentially isomerized D-Asp residue is located at the 2nd position 
from the N-terminus, which matches our expected location of a D-amino acid occurring in 
neuropeptide. This observation is in agreement with our hypothesis that the isomerase machinery 
in Aplysia may target the N-terminal. 
Other controls of this experiment include HPLC water sample labeled with Marfey’s 
reagent, and empty hydrolysis tubes going through hydrolysis and labeling process, as well as 
other biological samples hydrolyzed within the same acid hydrolysis experiment. Except for one 
biological sample that was located close to this sample in the hydrolysis vessel showing a minor 
D-Asp peak, no samples were detected of D-amino acids (data not shown). Therefore, the 
identification is more likely to be correct. 
The PRQFVa prohormone was first characterized by Furukawa Y. et al24  in collaboration 
with our group in 2003. PRQFVamide and four related pentapeptides were identified with 
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MALDI MS. With the use of immunohistochemistry and in situ hybridization, the PRQFVa 
prohormone was mapped in Aplysia CNS tissues. The structure of this prohormone is shown in 
Figure 6.,24 containing 33 copies of PRQFVamide peptide. SDAAFLETRHL is boxed in red near 
the C-terminal end of the prohormone, and no known functions of this peptide have been reported 
so far. 
From the mass list obtained from MALDI analysis of this particular fraction, D-Asp can 
also be traced back to the other possibility, SVDSDLD (m/z 750.5) from FMRFa precursor. This 
mass assignment is less likely because a possible sodium adduct of the major peptide RLRFH has 
the same m/z, and in biological samples, sodium adducted ions are not uncommon. 
Further experiments are needed to verify this data. More control experiments may also be 
required to exclude the possibility that this D-amino acid comes from unknown sources in the 
background. 
 
6.6 FUTURE WORK  
Several approaches have been created so far to determine if a peptide sample has a D-
amino acid. While each has specific advantages such as the low sample requirements for CE, and 
the robust ability to the MRM approach, the latter is the one that has the greatest likelihood to 
confirm D-AAs is peptides. In fact, several putative DAACPs have been observed. To confirm 
these results, more control experiments need to be conducted, and reproducibility needs to be 
tested. Our next experiments will likely be performed in the group by Itamar Livnat.  
First of all, these peptides will be purified from Aplysia cerebral ganglia extracts. Two-
stage HPLC separation will be performed with twenty animals as starting material, with the first 
stage being an analytical-scale reversed-phase crude fractionation using a C18 column, and the 
second stage will be using a capillary-scale hypercarb column which will provide significantly 
different selectivity. It is expected that peptides can be separated better using a different stationary 
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phase in the second stage than manipulating ion-pairing reagents or using methanol to replace 
acetonitrile in the second stage. 
Twenty fractions will be generated from the first stage, and MALDI MS will be used to 
screen these fractions and look for the target peptide. MS/MS will be performed to obtain 
sequence information of the m/z 1372.9 peptide to confirm the identity of this peptide.  
A crude fraction containing m/z 1372.9 will be subjected to the second-stage separation. 
Hopefully a relatively pure fraction of the target peptide can be identified. If this is the case, this 
fraction will be evaporated to dryness and reconstituted to 50 μL.  
10 μL out of the reconstituted fraction will be used for acid hydrolysis and chiral amino 
acid analysis. In this experiment, three controls will be included. The first one is a clean microvial 
for acid hydrolysis and Marfey’s reagent labeling in order to get the baseline noise from the 
chemicals (Marfey’s reagent, HCl, and solvents) and containers (glassware, eppendorf tubes, and 
hydrolysis vessel and gas lines); the second one will be a synthetic D-amino acid-containing 
peptide (or a D-amino acid) for the same hydrolysis experiment and subsequent labeling to 
observe the completion of the hydrolysis and any artificial racemization that might have happened 
in the process; and the third one will be directly derivatizing another 10 μL-aliquot of the 
reconstituted fraction to see if there are any free amino acids in the fraction.  
Another 10 μL aliquots can be used for a nano-scale LC-MS separation. Synthetic all-L 
form target peptide as well as expected epimers will be synthesized and their retention time will 
be compared to determine which epimer the endogenous peptide co-elutes with.  
Another possibility is to concentrate the sample and use it for tandem MS analysis. In this 
case, a synthetic all-L form target peptide and its epimers that need to be tested will be 
synthesized. Their fragmentation patterns in collision-induced dissociation (CID) tandem MS will 
be compared using the MALDI-TOF/TOF technique. Details about using the tandem MS method 
to distinguish peptide epimers are described in Chapter 5.  
The latter two methods can be used if the second-stage separation does not help purify the 
target peptide. These methods can be robust verification approaches even with unpurified 
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samples.  
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FIGURES AND TABLES 
 
 
 
Figure 6.1. Capillary electrophoresis separation of hydrolysate from synthetic GdFFD peptide. A 
small amount of racemized Asp can be detected, and the peak area is roughly 1:1:1:1 for the four 
constituent residues (figure courtesy of Nobutoshi Ota). 
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Figure 6.2. Schematic diagram showing two apparatus for acid hydrolysis. On the left is a 
reusable vacuum hydrolysis tube for liquid-phase hydrolysis available from Thermo Scientific 
(Pierce Protein Research Products, Rockford, IL). The branch on the side is connected to gas 
tubing to apply vacuum or inert gas. A usual hydrolysis condition is 108 centigrade for about 18 
hr. On the right is a TEM vapor-phase microwave acid hydrolysis system (Mathews, NC). A 
vessel which can hold up to 10 microvials for hydrolysis is used with this system, providing a fast 
and efficient vapor-phase hydrolysis method.    
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A 
 
B 
Figure 6.3. Manual Edman sequencing of NWFa (A) and NdWFa (B). Blank represents an HPLC 
run with just water instead of peptide samples. Acid hydrolysis converts Asn into Asp and 
amidated Phe into Phe. Peak assignment shown in the chromatograms is based on comparing 
sample runs with control runs (chromatograms for control runs are not shown). Some reviews and 
previews of residues from the previous and following cycles are observed.  
  
 161 
 
 
 
 
 
 
Figure 6.4. LC-MS/MS-MRM analysis on triple-quadrupole MS. This instrument consists of 
three quadrupoles. Q1 (first quadruple) is used for parent ion mass filtering. Ions with target m/z 
are selected to go through Q2 where collision happens to break down analytes into smaller pieces. 
One interfering ion (blue) with identical mass remains. The m/z selection in the third quadrupole 
filters out all the fragments of the blue analyte and leaves only a particular fragment of the green 
analyte for specific detection. Adapted from Lange et al. with permission.25 
(http://www.absciex.com/applications/drug-discovery-and-development-mass-spec/regulated-
bioanalysis/mrm3-quantitation.) 
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Figure 6.5. The reaction of Marfey’s reagent labeling. This process creates diastereomers which 
can be resolved with reversed-phase HPLC. Adapted from Marfey et al. with permission. 21 
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Figure 6.6. LC-MS/MS-MRM detection of Marfey’s reagent-labeled 39 amino acid enantiomers 
separated in one run. Different MRM channels are shown, with most containing one L-amino acid 
and its corresponding D-enantiomer, because the labeled L-amino acid and the D-enantiomer 
have the same fragmentation pattern and collision energy, judging from the Met case (data not 
shown). Leu and Ile are in one channel, and D-Leu and D-Ile are the only two enantiomers not 
baseline-separated. 
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Figure 6.7. LC-MS/MS-MRM analysis of synthetic GFFD standard and GdFFD standard, and a 
biological sample containing GdFFD. D-Phe is detected in the biological sample, which is a 
lower peak than L-Phe because other peptides within this unpurified biological sample may also 
contain an L-Phe and will all contribute to the L-Phe. 
  
 165 
 
 
 
 
 
Figure 6.8. LC-MS/MS-MRM analysis of a HPLC fraction from the cerebral ganglia after acid 
hydrolysis. D-Trp (not shown) and D-Asp are discovered in this sample. 
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Figure 6.9. The sequence and structure of the PRQFVa prohormone. M/z 1372.7 peptide is 
shown in the red box. Adapted from Furukawa et al. with permission.24 
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Table 6.1. Comparison of acid hydrolysis conditions among liquid-phase, 30-min vapor-phase 
and 2-min vapor-phase hydrolysis on yield and artificial racemization measured by capillary 
electrophoresis (data acquired by Nobutoshi Ota). 2-min vapor phase is chosen to be the method 
for capillary electrophoresis measurements of acid hydrolysates because of the speed, high yield 
and acceptable racemization rate. 
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Table 6.2. HPLC gradient used for LC-MS/MS-MRM runs. 
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Table 6.3. Amino acids analyzed with the LC-MS/MS-MRM method. The parent ion masses 
after Marfey’s reagent labeling, the signature product ions selected, and the corresponding 
collision energies to generate these product ions are listed. 
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Table 6.4. MALDI MS analysis of the HPLC fraction from cerebral ganglia. Two peptides that 
may contain D-Asp are highlighted. The table shows a list of peptides detected from MALDI MS 
analysis with mass match. Sequence information is obtained from an in-house neuropeptide 
database (Sweedler group, unpublished) based on mass match. Two peptides that may be 
responsible for the D-Asp detected with the LC-MS/MS-MRM method are highlighted. 
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CHAPTER 7  
 
CONCLUSIONS AND FUTURE DIRECTIONS 
The central dogma of molecular biology, a genius and revolutionary concept of the twentieth 
century, has provided a framework for understanding how a protein is made. Over the recent sixty 
years, we came to realize this concept was only our beginning to understanding the previously 
unappreciated complexity of the protein synthesis process. Modern ‘omics studies have filled in 
myriad details and elucidated a considerable number of previously unknown mechanisms through 
which the variety of protein products made from one string of genetic code can be expanded.  
 Post-translational modifications (PTMs), among these mechanisms are one of the most 
dynamic of these processes. Different from many other PTMs which involve addition of 
functional groups to enhance stability, solubility, and receptor binding,1 L-to-D epimerization is a 
unique way of creating different three dimensional structures. When the natural ligand is a D-
amino acid-containing peptide (DAACP), potency differences as high as several orders of 
magnitude have been observed between the DAACP and its all-L form counterpart. This can be 
explained by the lock-and-key model, or the shape-based match between signaling molecules and 
G-protein-coupled receptors (GPCR), which requires highly specific conformations. Almost all 
DAACPs discovered to date have shown significantly greater physiological effects than the all-L 
diastereomers, including the newly discovered GdFFD described in this study. Moreover, the 
enzyme degradation resistance and comparatively long half-life conferred by the incorporation of 
a D-amino acid suggest the involvement of DAACPs in cell-to-cell signaling.  
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 Although DAACPs may be important for the proper functions of more  pathways than we 
currently know, they are under-investigated due to the challenges with characterization. This 
study has presented a systematic and integrative approach for DAACP identification from 
biological samples as complex as the central nervous system. We have shown that this workflow 
is useful for a classic physiological model organism Aplysia, and preliminary studies have opened 
numerous opportunities to test many candidates for the presence of a D-amino acid. The 
multifaceted approach presented here functions with complex samples and does not require much 
prior information about the sample, and so other model organisms can be tested with this 
platform. Methods can be selected from this platform can be used once information including 
complexity, purity, and abundance of a particular sample becomes available.  
 Ultimately, our hypothesis that DAACPs are more common than we thought can be tested 
in aditional metazoan species including human. The fact that currently known members in the 
family span three phyla indicates this modification may be quite ancient and conserved across the 
Metazoa. In recent years, greater evidence supports the hypothesis that mammals may have 
DAACPs. The first mammalian DAACP reported was the C-type natriuretic peptide and the 
related peptidyl-aminoacyl-L/D-isomerase, found in the Australian duck-billed platypus 
(Ornithorhyncus anatinus).2-3 The frog Bombina isomerase-like polypeptide sequences, one of the 
three known enzymes responsible for L-to-D epimerization in peptides, have found analogs in 
databanks containing human proteomes. Consistent with this finding, detection of homologs of 
dermorphin and dermenkephalin (DAACPs isolated from the frog Phyllomedusa) have been 
indicated in rat brain tissues based on immunoreactivity and chromatographic properties.4 Recent 
studies have also shown that the mouse heart exhibits isomerase activity and converts several 
synthetic all L-peptides derived from the platypus defensin-like peptide into the expected 
DAACP.5 With all the information pointing toward a wide presence of DAACPs including in 
mammals, we expect to resolve these mysteries by systematically looking for these isomerized 
candidates.  
 In this thesis research, a series of analytical techniques have been established, including 
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survey-based screening for potential DAACPs from crude tissue samples, chiral amino acid 
analysis to verify the composition and chirality of the residues, and a tandem MS method to 
verify these identifications. These methods, compared to a range of existing analytical methods 
for analysis of peptide diastereomers in relatively simple mixtures, focuses on the complex nature 
of peptide samples from the CNS. We expect the range of analytical methods used to evaluate 
chirality to continue to expand. And we hope that the isomerases responsible for the chirality 
changes in Aplysia as well as in mammals to be revealed.  
 Further development of the current methods is expected. The screening step can be 
strengthened by incorporating carboxypeptidase digestion experiments which can identify 
DAACPs if the D-amino acid is close to the carboxyl terminal. This method, combined with the 
aminopeptidase digestion, will expand the range of candidates and reduce false negatives. 
Another source of DAACP candidates can come from chromatographic separations which are 
capable of resolving structural isomers. Although an HPLC separation alone is not the first choice 
for screening purposes due to the limited resolving space and the potential absence of one of the 
diastereomers, in peptidomics experiments whenever two peaks are observed showing the same 
m/z, these peaks are worth following up for further analysis. Ion mobility spectrometry is a 
promising technique for studies of diastereomers. In collaboration with Clemmer’s group in 
Indiana University, we are expecting to improve the resolution with standards and be able to 
analyze biological samples with minimal formation of peptide clusters.   
 Future research efforts combining bioinformatics, targeted imaging experiments, and 
sampling protocols will be developed in conjunction with mass spectrometric measurements in 
stimulation-induced release, microdialysates, as well as tissue homogenates, to enable trace-level 
detection and characterization of DAAPs from specific samples. With the availability of these 
powerful analytical approaches, sample preparation methodologies, and the knowledge about the 
neuropeptides in the various organisms, chiral characterizations of these neuropeptides will be 
conducted in the metazoan. The newly discovered DAACPs will be assayed for their 
physiological functions, leading to a better understanding of the significance of this modification. 
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Immunohistochemistry and in situ hybridization staining will be used to probe the distribution of 
the DAACPs and the all-L forms, which will not only help to make functional indications but also 
assist with investigating conformational specificity in the secretion and transportation of 
neuropeptides. Characterization of DAACPs that are much more potent than the all-L 
counterparts will uncover receptor-ligand interactions that are previously unaccounted for, and 
even reveal the native binding partners of orphan receptors.  
 Specifically, with the discovery funnel described in this study, we will be able to 
investigate the peptidomes of several important model organisms ranging from structurally 
simple marine invertebrates, flatworms, more complex tissues such as the songbird brain, and 
mammalian hypothalamus tissues, with previously unappreciated dimensions that not only 
encompass sequence information but also take structures into consideration. Once DAACP 
discoveries are validated, functional tests will be carried out with our collaborators in the future 
using electrophysiological tools based on the specific functional context.  
 In particular, the hypothalamic tissues such as the suprachiasmatic nucleus (SCN) will be 
a great model for a systematic investigation of DAACP synthesis, release, and physiological 
functions. The Sweedler group, in collaboration with the Gillette laboratory at the University of 
Illinois at Urbana-Champaign, has been characterizing the peptidome of the SCN, and we have 
reported more than two hundred peptides from the SCN, including those that are released in an 
activity dependent manner. 6-8 We already have found several isomers that co-elute in the SCN 
and will test these to see if they contain a D-amino acid. We have the ability to test the 
functioning of putative DAACPs as circadian timing makes a bioassay framework to test the 
effects of certain neuropeptides on the phase shift of neuron firing patterns.6  
Although DAACPs have been found in more than 15 animal species, the total number 
remains low. Given the phylogenetic distance of the three species, and the scattered discoveries of 
DAACPs in quite different animal species, it is reasonable to think this PTM has an ancient 
evolutionary origin and their distribution is wider than we currently appreciate. Enzyme 
mechanisms responsible for this PTM have been discovered in three animal species, but questions 
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regarding substrate specificity of these enzymes and how conserved these mechanisms are across 
species remain unanswered. Once a significant number of DAACPs are identified, further studies 
will be possible; bioinformatics tools trained on a number of DAACP cases may be able to 
identify consensus site of isomerization or a signal sequence that flags a certain peptide to be 
modified. With more DAACPs and isomerases identified, comparative studies can be carried out 
which will elucidate the evolutionary significance of this modification. 
 The analytical tools developed in this study may also be used for analysis of other D-
amino acid-containing proteins that are produced in non-enzymatic but age-related processes, 
such as various human proteins including β-amyloid protein in the brain and α-crystallin in the 
lens.9 Although these are not the focus of this study, the value of measuring D-amino acid content 
in these proteins is not limited to dating a tissue. Given previously reported relevance of D-amino 
acids in β-amyloid protein with the pathologic aggregation and fibril formation which are 
believed to lead to the Alzheimer’s disease,10 carefully designed and well controlled 
measurements may be able to reveal previously unknown mechanisms for this disease.  
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